Manuscripts (567 of 567)

Utilization of proteomic surrogates for early detection of unexpected drug benefits
Jessica Chadwick, Colin Berry, Meredith A Carpenter, Geeta Gulati, Siri Lagethon Heck, Michael A Hinterberg, Rury R Holman, Matthew M Y Lee, Torbjørn Omland, Clare Paterson, Mark C Petrie, Naveed Sattar, Svati H Shah, Sama Shrestha, Harald Sourij, Emma V Troth, Victoria Vinje, Stephen A Williams
J Clin Pharmacol. 2025. Epub:06-Jul-2025. PMID:40619592. doi:10.1002/jcph.70077

Glucocorticoid-induced hyperglycaemia in hospitalised adults: A matched cohort study (2013-2023).
Golubic R, Mumbole H, Coleman RL, Rea R, Mathur R, Caleyachetty R, Adler AI.
Diabetes Obes Metab. 2025. Epub:02-Apr-2025. PMID:40171899. doi:10.1111/dom.16378

Glucocorticoid treatment and new-onset hyperglycaemia and diabetes in people living with chronic obstructive pulmonary disease: A systematic review and meta-analysis
Rajna Golubic, Hudson Mumbole, Mouhamad Hussein Ismail, Alwyn Choo, Olivia Baker, Karyna Atha, Sarah Chew Sue Mei, Arjun Raj, Preethu Anand, Nwe Oo Aung, Niraj S. Kumar, Tulika Nahar, Ruth L. Coleman, Jeremy W. Tomlinson, Najib Rahman, Rishi Caleyachetty, Amanda Adler
Diabetic Medicine 2024. Epub:06-Dec-2024. doi:10.1111/dme.15475

Evaluating prediction of short-term tolerability of five type 2 diabetes drug classes using routine clinical features: UK population-based study
Pedro Cardoso, Katie G Young, Rhian Hopkins, Bilal A Mateen, Ewan R Pearson, Andrew T Hattersley, Trevelyan J McKinley, Beverley M Shields, John M Dennis; MASTERMIND consortium
Diabetes Obes Metab. 2025;27:4320-4329. Published:Aug-2025. Epub:16-May-2025. PMID:40375735. doi:10.1111/dom.16470

Risk factors for bone fractures in type 2 diabetes and the impact of once-weekly exenatide: Insights from an EXSCEL post-hoc analysis
Erenesto Maddaloni, Ruth L. Coleman, Rury R. Holman
Diabetes Res Clin Pract. 2025;223:112125. Published:May-2025. Epub:26-Mar-2025. PMID:40154887. doi:10.1016/j.diabres.2025.112125

Response to Comments on Maddaloni et al. Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. Diabetes Care 2025;48:235-242
Ernesto Maddaloni, Maggie Nguyen, Svati H. Shah, Rury R. Holman
Diabetes Care 2025;48:e61-e62. Published:01-Apr-2025. doi:10.2337/dci24-0109

Identification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities
Loesch DP, Garg M, Matelska D, Vitsios D, Jiang X, Ritchie SC, Sun BB, Runz H, Whelan CD, Holman RR, Mentz RJ, Moura FA, Wiviott SD, Sabatine MS, Udler MS, Gause-Nilsson IA, Petrovski S, Oscarsson J, Nag A, Paul DS, Inouye M.
Nat Commun. 2025;16:2124. Published:03-Mar-2025. Epub:03-Mar-2025. PMID:40032831. doi:10.1038/s41467-025-56695-z

A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study
John M Dennis, Katherine G Young, Pedro Cardoso, Laura M Gu?demann, Andrew P McGovern, Andrew Farmer, Rury R Holman, Naveed Sattar, Trevelyan J McKinley, Ewan R Pearson, Angus G Jones, Beverley M Shields, Andrew T Hattersley, on behalf of the MASTERMIND Consortium
Lancet 2025;405:701-714. Published:01-Mar-2025. Epub:25-Feb-2025. PMID:40020703. doi:10.1016/S0140-6736(24)02844-7

Cardiovascular Outcomes with Exenatide in Type 2 Diabetes according to Ejection Fraction: the EXSCEL trial
João Sérgio Neves, Ana Rita Leite, Robert J. Mentz, Rury R. Holman, Faiez Zannad, Javed Butler, Milton Packer, João Pedro Ferreira
Eur J Heart Fail 2025;27:540-551. Published:Mar-2025. Epub:09-Oct-2024. PMID:39381950. doi:10.1002/ejhf.3478

Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL
Erenesto Maddaloni, Maggie Nguyen, Svati H Shah, Rury R Holman
Diabetes Care 2025;48:235-242. Published:01-Feb-2025. Epub:22-Nov-2024. PMID:39576722. doi:10.2337/dc24-1455

The science of diabetes and a life of trials: The 2024 Banting Medal for Scientific Achievement Lecture
Rury R. Holman
Diabetes 2025;74:164-174. Published:01-Feb-2025. PMID:39836885. doi:10.2337/db24-0719

The legacy effect of hyperglycaemia in type 2 diabetes - Authors' reply
Amanda I Adler, Ruth L Coleman, William N Whiteley, Rury R Holman
Lancet 2025;405:29. Published:04-Jan-2025. doi:10.1016/S0140-6736(24)02384-5

Using QALYs as an outcome for assessing global prediction accuracy in diabetes simulation models
Helen A Dakin, Ni Gao, José Leal, Rury R Holman, An Tran-Duy, Philip Clarke
Med Decis Making 2025;45:45-59. Published:Jan-2025. Epub:30-Oct-2024. PMID:39474832. doi:10.1177/0272989X241285866

Effects of Intensive Blood Pressure Treatment on Orthostatic Hypertension: An Individual Level Meta-analysis
Stephen P Juraschek, Jiun-Ruey Hu, Jennifer L Cluett, Carol Mita, Lewis A Lipsitz, Lawrence J Appel, Nigel S Beckett, Barry R Davis, Rury R Holman, Edgar R Miller 3rd, Kenneth J Mukamal, Ruth Peters, Jan A Staessen, Addison A Taylor, Jackson T Wright Jr, William C Cushman
BMJ 2025;388:e080507. PMID:40132860. doi:10.1136/bmj-2024-080507

Great Debate: Pre-diabetes is not an evidence-based treatment target for cardiovascular risk reduction
Nikolaus Marx, Lars Rydén, Massimo Federici, Katharina Marx-Schütt, Marlo Verket, Dirk Müller-Wieland, Hertzel C. Gerstein, Juliana Chan, Francesco Cosentino, Rury R. Holman, Linda Mellbin , Kausik K. Ray, Eberhard Standl, Subodh Verma, David Wood, Jaakko Tuomilehto and Raffaele De Caterina
European Heart Journal 2024;45:5117-5126. Published:21-Dec-2024. Epub:10-Oct-2024. PMID:39387537. doi:10.1093/eurheartj/ehae533

Younger-onset compared with later-onset type 2 diabetes: an analysis of the UK Prospective Diabetes Study (UKPDS) with up to 30 years of follow-up (UKPDS 92)
Beryl Lin, Ruth L. Coleman, Fiona Bragg, Ernesto Maddaloni, Rury R. Holman, Amanda I. Adler
Lancet Diabetes Endocrinol. 2024;12:904-914. Published:Dec-2024. Epub:23-Oct-2024. PMID:39461360. doi:10.1016/S2213-8587(24)00242-0

Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial
Ivan Koychev, Graham Reid, Maggie Nguyen, Robert J. Menz, Dan Joyce, Svati H. Sha, Rury R. Holman
Alzheimers Res Ther. 2024;16:212. Published:02-Oct-2024. PMID:39358806. doi:10.1186/s13195-024-01573-x

Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial
Abderrahim Oulhaj, Faisal Aziz, Abubaker Suliman, Kathrin Eller, Rachid Bentoumi, John B. Buse, Wael Al Mahmeed, Dirk von Lewinski, Ruth L. Coleman, Rury R. Holman, Harald Sourij
Diabetes Obes Metab. 2024;26:4602-4612. Published:Oct-2024. Epub:31-Jul-2024. PMID:39086032. doi:10.1111/dom.15817

Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management
Ni Gao, Helen A. Dakin, Rury R. Holman, Lee Ling Lim, José Leal, Philip Clarke
PharmacoEconomics 2024;42:1017-1028. Published:Sep-2024. Epub:26-Jun-2024. PMID:38922488. doi:10.1007/s40273-024-01398-4

Post-trial Monitoring of a Randomised Controlled Trial of Intensive Glycaemic Control in Type 2 Diabetes Extended from 10 to 24 years (UKPDS 91)
Amanda I. Adler, Ruth L. Coleman, Jose Leal, Will N. Whiteley, Philip Clarke, Rury R. Holman
Lancet 2024;404:145-55. Published:13-Jul-2024. Epub:18-May-2024. PMID:38772405. doi:10.1016/S0140-6736(24)00537-3

Are the cardiovascular properties of GLP-1 receptor agonists differentially modulated by sulfonylureas? insights from post-hoc analysis of EXSCEL
K.M. Gooding, S. Stevens, Y. Lokhnygina, A. Giczewska, A.C. Shore, R.R. Holman
Diabetes Res Clin Pract. 2024;212:111685. Published:02-May-2024. Epub:25-Apr-2024. PMID:38670496. doi:10.1016/j.diabres.2024.111685

Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Pedro Cardoso , Katie G. Young, Anand T.N. Nair, Rhian Hopkins, Andrew McGovern, Eram Haider, Piyumanga Karunaratne, Louise Donnelly, Naveed Sattar, Rury R. Holman, Jack Bowden, Andrew T. Hattersley, Ewan R. Pearson, Angus G. Jones, Beverley M. Shields, Trevelyan J. McKinley, John M. Dennis; MASTERMIND consortium
Diabetologia 2024;67:822-836. Published:May-2024. Epub:22-Feb-2024. PMID:38388753. doi:10.1007/s00125-024-06099-3

Regional variation in cause of death in patients with type 2 diabetes: insights from EXSCEL: Cause of Death in Type 2 Diabetes
Vishal N Rao, Abhinav Sharma, Amanda Stebbins, John B. Buse, Brian G. Katona, Neha J. Pagidipati, Rury R. Holman, Adrian Hernandez, Robert J. Mentz, Renato D. Lopes
Am Heart J. 2024;271:123-135. Published:May-2024. Epub:21-Feb-2024. PMID:38395292. doi:10.1016/j.ahj.2024.02.013

Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data
Patrick Bidulka, David G Lugo-Palacios, Orlagh Carroll, Stephen O'Neill, Amanda I Adler, Anirban Basu, Richard J Silverwood, Jonathan W Bartlett, Dorothea Nitsch, Paul Charlton, Andrew Briggs, Liam Smeeth, Ian J Douglas, Kamlesh Khunti, Richard Grieve
BMJ 2024;10. Epub:08-May-2024
[Full text]

Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults
Ivan Koychev , Amanda I Adler, Paul Edison, Brian Tom, Joanne E Milton, Joe Butchart, Adam Hampshire, Charles Marshall, Elizabeth Coulthard, Henrik Zetterberg, Peter Hellyer, Francesca Cormack, Benjamin R Underwood, Catherine J Mummery, Rury R Holman
BMJ Open 2024;14:e081401. doi:10.1136/bmjopen-2023-081401

Comparison of Medical Resources and Costs among Patients with Coronary Heart Disease and Impaired Glucose Tolerance in the Acarbose Cardiovascular Evaluation (ACE) Trial
Frauke Becker, Liam Mc Morrow, Jose Leal, Ruth L. Coleman, Hertzel C. Gerstein, Lars Rydén, Stefan Schröder, Alastair M. Gray, Rury R. Holman; for the ACE Study Group
Journal of Diabetes 2023;16:e13473. Published:Feb-2024. Epub:02-Nov-2023. PMID:37915263. doi:10.1111/1753-0407.13473

Sex-Specific Effects of Blood Pressure Lowering Pharmacotherapy for the Prevention of Cardiovascular Disease: An Individual Participant-Level Data Meta-Analysis
Zeinab Bidel, Milad Nazarzadeh, Dexter Canoy, Emma Copland, Eva Gerdts, Mark Woodward, Ajay K Gupta, Christopher M Reid, William C. Cushman, Kristian Wachtell, Koon Teo, Barry R Davis, John Chalmers, Carl J Pepine, Kazem Rahimi; Blood Pressure Lowering Treatment Trialists’ Collaboration
Hypertension 2023;80:2293-2302. Published:Nov-2023. Epub:24-Jul-2023. PMID:37485657. doi:10.1161/HYPERTENSIONAHA.123.21496

Orthostatic Hypotension, Hypertension Treatment, and Cardiovascular Disease. An Individual Participant Meta-Analysis
Stephen P Juraschek, Jiun-Ruey Hu, Jennifer L Cluett, Anthony M Ishak, Carol Mita, Lewis A. Lipsitz, Lawrence J Appel, Nigel S Beckett, Ruth L. Coleman, William C. Cushman, Barry R Davis, Greg Grandits, Rury R. Holman, Edgar R Miller 3rd, Ruth Peters, Jan A. Staessen, Addison A. Taylor, Jackson T Wright Jr, Kenneth J Mukamal
JAMA 2023;330:1459-1471. Published:17-Oct-2023. PMID:37847274. doi:10.1001/jama.2023.18497

Timing of SGLT2i initiation after acute myocardial infarction
Dirk von Lewinski, Ewald Kolesnik, Faisal Aziz, Martin Benedikt, Norbert J. Tripolt, Markus Wallner, Peter N. Pferschy, Friederike von Lewinski, Nora Schwegel, Rury R. Holman, Abderrahim Oulhaj, Deddo Moertl, Jolanta Siller-Matula and Harald Sourij
Cardiovasc Diabetol. 2023;22:269. Published:30-Sep-2023. Epub:30-Sep-2023. PMID:37777743. doi:10.1186/s12933-023-02000-5

Mitochondrial Metabolites Predict Major Adverse Cardiovascular Events in Individuals with Type 2 Diabetes Mellitus
Jessica A Regan, Robert J Mentz, Maggie Nguyen, Jennifer B Green, Lauren K Truby, Olga Ilkayeva, Christopher Newgard, John B Buse, Harald Sourij, C David Sjostrom, Naveed Sattar, Robert W McGarrah, Yinggan Zheng, Darren K McGuire, Eberhard Standl, Paul Armstrong, Eric Peterson, Adrian Hernandez, Rury R Holman, Svati H Shah
JCI Insight 2023;8:e168563. Published:08-Sep-2023. Epub:08-Aug-2023. PMID:37552540. doi:10.1172/jci.insight.168563

Aetiology of Type 2 diabetes in people with a 'normal' body mass index: Testing the Personal Fat Threshold Hypothesis
Roy Taylor, Alison C. Barnes, Kieren Hollingsworth, Keaton M. Irvine, Alexandra S. Solovyova, Lucy G. Clark, Tara L.Kelly, Carmen Martin-Ruiz, Davide Romeres, Albert Koulman, Claire L Meek, Benjamin Jenkins, Claudio Cobelli, Rury R. Holman
Clin Sci (Lond). 2023;137:1333-1346. Published:31-Aug-2023. Epub:18-Aug-2023. PMID:37593846. doi:10.1042/CS20230586

Association of osteocalcin, osteoprotegerin and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes
Ernesto Maddaloni, Lucia Coraggio, Rocco Amendolara, Marco G. Baroni, Maria G. Cavallo, Massimiliano Copetti, Efisio Cossu, Paola D’Angelo, Luca D’Onofrio, Salvatore De Cosmo, Frida Leonetti, Susanna Morano, Lelio Morviducci, Nicola Napoli, Sabrina Prudente, Giuseppe Pugliese, Kyoungmin Park, Rury R. Holman, Vincenzo Trischitta, Raffaella Buzzetti for the SUMMER Study in Diabetes Group
Diabetes Metab Res Rev. 2023;39:e3632. Published:Jul-2023. Epub:06-Mar-2023. PMID:36880127. doi:10.1002/dmrr.3632

Sex differences in complications, care, and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Jennifer B. Green, Peter Merrill, Yuliya Lokhnygina, Robert J. Mentz, Joakim Alfredsson, Rury R. Holman; EXSCEL Study Group
Diabetes Obes Metab. 2023;25:1473-1484. Published:Jun-2023. Epub:14-Feb-2023. PMID:36700460. doi:10.1111/dom.14993

Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial
Moritz J. Hundertmark, Amanda Adler, Charalambos Antoniades, Ruth Coleman, Julian L. Griffin, Rury R. Holman, Hanan Lamlum, Jisoo Lee, Daniel Massey, Jack J.J.J. Miller, Joanne E. Milton, Shveta Monga, Ferenc E. Mózes, Areesha Nazeer, Betty Raman, Oliver Rider, Christopher T. Rodgers, Ladislav Valkovic, Eleanor Wicks, Masliza Mahmod, Stefan Neubauer
Circulation 2023;147:1654-1669. Published:30-May-2023. Epub:18-Apr-2023. PMID:37070436. doi:10.1161/CIRCULATIONAHA.122.062021

Impact of baseline kidney function on the effects of SGLT2 inhibitors on kidney and heart failure outcomes: a systematic review and meta-analysis of randomized controlled trials
Ernesto Maddaloni, Ilaria Cavallari, Ylenia La Porta, Alessandro Appetecchia, Luca D’Onofrio, Francesco Grigioni, Raffaella Buzzetti, Rury R. Holman
Diabetes Obes Metab. 2023;25:1341-1350. Published:May-2023. Epub:26-Jan-2023. PMID:36700422. doi:10.1111/dom.14986

Joint longitudinal and time-to-event modeling compared with standard Cox modeling in patients with type 2 diabetes with and without established cardiovascular disease: an analysis of the EXSCEL trial
Abderrahim Oulhaj, Faisal Aziz, Abubaker Suliman, Nayyar Iqbal, Ruth L Coleman, Rury R Holman, Harald Sourij
Diabetes Obes Metab. 2023;25:1261-1270. Published:May-2023. Epub:12-Jan-2023. PMID:36635232. doi:10.1111/dom.14975

Time-Dependent Event Accumulation in a Cardiovascular Outcome Trial of Patients with Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease
M. Angelyn Bethel, Harald Sourij, Susanna R. Stevens, Karen Hannan, Yuliya Lokhnygina, Amanda I. Adler, Eric D. Peterson, Rury R. Holman, Renato D. Lopes
Cardiovasc Diabetol. 2023;22:72. Published:28-Mar-2023. PMID:36978066. doi:10.1186/s12933-023-01802-x

11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial
Nantia Othonos, Riccardo Pofi, Anastasia Arvaniti, Sarah White, Ilaria Bonaventura, Nikolaos Nikolaou, Ahmad Moolla, Thomas Marjot, Roland H Stimson, André P van Beek, Martijn van Faassen, Andrea M Isidori, Elizabeth Bateman, Ross Sadler, Fredrik Karpe, Paul M Stewart, Craig Webster, Joanne Duffy, Richard Eastell, Fatma Gossiel, Thomas Cornfield, Leanne Hodson, K Jane Escott, Andrew Whittaker, Ufuk Kirik, Ruth L Coleman, Charles A B Scott, Joanne E Milton, Olorunsola Agbaje, Rury R Holman, Jeremy W Tomlinson
Nat Commun. 2023;14:1025. Published:23-Feb-2023. Epub:23-Feb-2023. PMID:36823106. doi:10.1038/s41467-023-36541-w

Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study
Beverley M. Shields, John M. Dennis, Catherine D. Angwin, Fiona Warren, William E. Henley, Andrew J. Farmer, Naveed Sattar, Rury R. Holman, Angus G. Jones, Ewan R. Pearson, Andrew T. Hattersley & TriMaster Study group
Nat Med. 2023;29:376-383. Published:Feb-2023. Epub:07-Dec-2022. PMID:36477733. doi:10.1038/s41591-022-02120-7

Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study
Beverley M. Shields, Catherine D. Angwin, Maggie H. Shepherd, Nicky Britten, Angus G. Jones, Naveed Sattar, Rury Holman, Ewan R. Pearson & Andrew T. Hattersley
Nat Med. 2023;29:384-391. Published:Feb-2023. Epub:07-Dec-2022. PMID:36477734. doi:10.1038/s41591-022-02121-6

Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study
John M Dennis, Katherine G Young, Andrew P McGovern, Bilal A Mateen, Sebastian J Vollmer, Michael D Simpson, William E Henley, Rury R Holman, Naveed Sattar, Ewan R Pearson, Andrew T Hattersley, Angus G Jones, Beverley M Shields, on behalf of the MASTERMIND consortium
Lancet Digit Health 2022;4:e873-83. Published:Dec-2022. Epub:14-Nov-2021. PMID:364279. doi:10.1016/S2589-7500(22)00174-1

A brief history of the UK Prospective Diabetes Study
Rury Holman, for the UKPDS Group
Br J Diabetes 2022;22:S32-S35. Published:Dec-2022. doi:10.15277/bjd.2022.359

Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes - Authors' reply
Milad Nazarzadeh, Amanda I Adler, John Chalmers, Rury R Holman, Kazem Rahimi
Lancet Diabetes Endocrinol. 2022;10:841-842. Published:Dec-2022. PMID:36427521. doi:10.1016/S2213-8587(22)00310-2

Empagliflozin in acute Myocardial Infarction: the EMMY trial
Dirk von Lewinskia, Ewald Kolesnika, Norbert J. Tripoltb, Peter N. Pferschy, Martin Benedikta, Markus Wallnera, Hannes Alberd, Rudolf Bergere, Michael Lichtenauer, Christoph H. Saelyg, Deddo Moertlh, Pia Auerspergh,i, Christian Reiterj, Thomas Riederk, Jolanta M. Siller-Matulal, Gloria M. Gagerl, Matthias Hasunm, Franz Weidingerm, Thomas R. Pieberb, Peter M Zechnern, Markus Herrmanno, Andreas Zirlika, Rury R. Holman, Abderrahim Oulhaj, Harald Sourij on behalf of the EMMY Investigators
Eur Heart J. 2022;43:4421-4432. Published:01-Nov-2022. Epub:29-Aug-2022. PMID:36036746. doi:10.1093/eurheartj/ehac494

Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events
Jessica A Regan, Lauren K Truby, Usman A Tahir, Daniel H Katz, Maggie Nguyen, Lydia Coulter Kwee, Shuliang Deng, James G Wilson, Robert J Mentz, William E Kraus, Adrian F Hernandez, Robert E Gerszten, Eric D Peterson, Rury R Holman, Svati H Shah
Sci Rep. 2022;12:20072. Published:Nov-2022. PMID:36418363. doi:10.1038/s41598-022-24226-1

Risk prediction models for incident type 2 diabetes in Chinese people with intermediate hyperglycemia: a systematic literature review and external validation study
Shishi Xu, Ruth L. Coleman, Qin Wan, Yeqing Gu, Ge Meng, Kun Song, Zumin Shi, Qian Xie, Jaakko Tuomilehto, Rury R. Holman, Kaijun Niu and Nanwei Tong
Cardiovasc Diabetol. 2022;21:182. Published:13-Sep-2022. PMID:36100925. doi:10.1186/s12933-022-01622-5

Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis
Milad Nazarzadeh, Zeinab Bidel, Dexter Canoy, Emma Copland, Derrick A Bennett, Abbas Dehghan, George Davey Smith, Rury R. Holman, Mark Woodward, Ajay Gupta, Amanda Adler, Malgorzata Wamil, Naveed Sattar, Richard J McManus, Koon Teo, Barry R Davis, John Chalmers, Carl J. Pepine, Kazem Rahimi, On behalf of the Blood Pressure Lowering Treatment Trialists’ Collaboration
Lancet Diabetes Endocrinol. 2022;10:645-54. Published:Sep-2022. Epub:22-Jul-2022. PMID:35878651. doi:10.1016/S2213-8587(22)00172-3

Development and Validation of a Model to Predict Cardiovascular Death, Nonfatal Myocardial Infarction, or Nonfatal Stroke in Patients with Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease
Susanna R. Stevens, Matthew W. Segar, Ambarish Pandey, Yuliya Lokhnygina, Jennifer B. Green, Darren K. McGuire, Eberhard Standl, Eric D. Peterson, Rury R. Holman
Cardiovasc Diabetol. 2022;21:166. Published:27-Aug-2022. PMID:36030198. doi:10.1186/s12933-022-01603-8

Antihypertensive drug effects on long- term blood pressure: an individual- level data meta- analysis of randomised clinical trials
Canoy D, Copland E, Nazarzadeh M, Ramakrishnan R, Pinho-Gomes AC, Salam A, Dwyer JP, Farzadfar F, Sundström J, Woodward M, Davis BR, Rahimi K; Blood Pressure Lowering Treatment Trialists' Collaboration; Blood Pressure Lowering Treatment Trialists Collaboration.
Heart 2022;108:1281-1289. Published:27-Jul-2022. Epub:20-Jan-2022. PMID:35058294. doi:10.1136/heartjnl-2021-320171

Health utilities in Chinese patients with coronary heart disease and impaired glucose tolerance (ACE): A longitudinal analysis of a randomized, double-blind, placebo-controlled trial
José Leal, Fraucke Becker, Lee-Ling Lim, Rury R. Holman, Alastair M. Gray
J Diabetes 2022;14:455-464. Published:Jul-2022. PMID:35876124. doi:10.1111/1753-0407.13294

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Timothy M. E. Davis, Anna Giczewska, Yuliya Lokhnygina, Robert J. Mentz, Naveed Sattar, Rury R. Holman and for the EXSCEL Study Group
Cardiovasc Diabetol. 2022;21:116. Published:27-Jun-2022. PMID:35761271. doi:10.1186/s12933-022-01555-z

Validation of the WATCH- DM and TRS- HFDM Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis
Matthew W. Segar, Kershaw V. Patel, Anne S. Hellkamp, Muthiah Vaduganathan, Yuliya Lokhnygina, Jennifer B. Green, Siu-Hin Wan, Ahmed A. Kolkaila, Rury R. Holman, Eric D. Peterson, Vaishnavi Kannan, Duwayne L. Willett, Darren K. McGuire and Ambarish Pandey
J Am Heart Assoc. 2022;11:e024094. Published:07-Jun-2022. Epub:03-Jun-2022. PMID:35656988. doi:10.1161/JAHA.121.024094

Genomic editing of metformin efficacy-associated genetic variants in SLC47A1 does not alter SLC47A1 expression
Kalamajski S, Huang M, Dalla-Riva J, Keller M, Dawed AY, Hansson O, Pearson ER, MetGen Plus Consortium, Mulder H, Franks PW
Human Molecular Genetics 2022;31:491-498. Published:15-Feb-2022. Epub:09-Sep-2021. PMID:34505146. doi:10.1093/hmg/ddab266

Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: a cost-utility analysis based on the EXSCEL trial
Frauke Becker, Helen A. Dakin, Shelby D. Reed, Yanhong Li, José Leal, Stephanie M. Gustavson, Eric Wittbrodt, Adrian F. Hernandez, Alastair M. Gray, Rury R. Holman
Diabetes Res Clin Pract. 2022;183:109152. Published:01-Jan-2022. Epub:21-Nov-2021. PMID:34813910. doi:10.1016/j.diabres.2021.109152

The effect of fenofibrate therapy on laser treatment for diabetic retinopathy: a meta-analysis of randomized controlled trials
David Preiss, Enti Spata, Rury R. Holman, Ruth L. Coleman, Laura Lovato, Henry Ginsberg, Jane Armitage
Diabetes Care 2022;45:e1-e2. Published:Jan-2022. Epub:07-Dec-2021. PMID:34876531. doi:10.2337/dc21-1439

Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine
Abhinav Sharma, Yinggan Zheng, Justin A Ezekowitz, Cynthia M Westerhout, Jacob A Udell, Shaun G Goodman, Paul W Armstrong, John B Buse, Jennifer B Green, Robert G Josse, Keith D Kaufman, Darren K McGuire, Giuseppe Ambrosio, Lee-Ming Chuang, Renato D Lopes, Eric D Peterson, Rury R Holman
Diabetes Care 2022;45:04-212. Published:Jan-2022. Epub:29-Oct-2021. PMID:34716214. doi:10.2337/dc20-2806

NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma
Amanda I Adler, Samuel Slayen, Heather Stegenga, Yelan Guo, Richard Diaz, Nicky J Welton, Nigel Westwood, Iolo Doull, Charles Crawley
Lancet Resp Med 2022;1-2. Epub:18-Aug-2022. doi:10.1016/S2213-2600(22)00301-0

A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk
Stephen A. Williams, Rachel Ostroff, Michael Hinterberg, Joseph Coresh, Christie M. Ballantyne, Kunihiro Matsushita, Christian E. Mueller, Joan Walter, Christian Jonasson, Rury R. Holman, Svati H. Shah, Naveed Sattar, Roy Taylor, Michael E. Lean, Shintaro Kato, Hiroaki Shimokawa, Yasuhiko Sakata, Kotaro Nochioka, Chirag R. Parikh, Steven D. Coca, Jessica Chadwick, Yolanda Hagar, Missy Simpson, Jeremy Primus, Natasha Kureshi, Nelson P. Trujillo, Peter Ganz
Sci Transl Med. 2022;14:eabj9625. Epub:06-Apr-2022. PMID:35385337. doi:10.1126/scitranslmed.abj9625

Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial
Marc D. Samskya, Robert J. Mentza, Amanda Stebbins, Yuliya Lokhnygina, Aaron W. Aday, Neha J. Pagidipati, W. Schuyler Jonesa, Brian G. Katona, Manesh R. Patel, Rury R. Holman, Adrian F. Hernandez, Jorge Antonio Gutierrez
Atherosclerosis 2021;338:1-6. Published:Dec-2021. Epub:03-Nov-2021. PMID:34741929. doi:10.1016/j.atherosclerosis.2021.10.011

Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas
Adem Y Dawed, Sook Wah Yee, Kaixin Zhou, Nienke van Leeuwen, Yanfei Zhang, Moneeza K Siddiqui, Amy Etheridge, Federico Innocenti, Fei Xu, Josephine H Li, Joline W Beulens, Amber A van der Heijden, Roderick C Slieker, Yu-Chuan Chang, Josep M Mercader, Varinderpal Kaur, John S Witte, Ming Ta Michael Lee, Yoichiro Kamatani, Yukihide Momozawa, Michiaki Kubo, Colin N A Palmer, Jose C Florez, Monique M Hedderson, Leen M 't Hart, Kathleen M Giacomini, Ewan R Pearson, for MetGen Plus, for the DIRECT Consortium
Diabetes Care 2021;44:2673-2682. Published:Dec-2021. Epub:04-Oct-2021. PMID:34607834. doi:10.2337/dc21-1152

Nintedanib for treating progressive fibrosing interstitial lung diseases
Amanda I Adler, Yelan Guo, Aminata Thiam, Nicole Elliot, Sanjeev Patel
The Lancet 2021;1-2. Published:23-Nov-2021. Epub:18-Nov-2021. doi:10.1016/S2213-2600(21)00517-8

Protocol for an observational cohort study investigating personalised medicine for intensification of treatment in people with type 2 diabetes mellitus: the PERMIT study
Patrick Bidulka, Stephen O’Neill, Anirban Basu, Samantha Wilkinson, Richard J Silverwood, Paul Charlton, Andrew Briggs, Amanda I Adler, Kamlesh Khunti, Laurie A Tomlinson, Liam Smeeth, Ian J Douglas, Richard Grieve
BMJ Open 2021;11:1-9. Published:05-Oct-2021. Epub:27-Sep-2021. doi:10.1136/bmjopen-2020-046912

Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90)
Jose Leal, Maria Alva, Vanessa Gregory, Alison Hayes, Borislava Mihaylova, Alastair M Gray, Rury R. Holman, Philip Clarke
Diabet Med. 2021;38:e14656. Published:Oct-2021. Epub:23-Jul-2021. PMID:34297424. doi:10.1111/dme.14656

Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88
Marcus Lind, Henrik Imberg, Ruth L. Coleman, Olle Nerman, and Rury R. Holman
Diabetes Care 2021;44:2231-2237. Published:Oct-2021. Epub:08-Jul-2021. PMID:34244332. doi:10.2337/dc20-2439

Predicting Major Adverse Limb Events in Individuals With Type 2 Diabetes: Insights From the EXSCEL Trial
E. Hope Weissler, Robert M. Clare, Yuliya Lokhnygina, John B. Buse, Shaun G. Goodman, Brian Katona, Nayyar Iqbal, Neha J. Pagidipati, Naveed Sattar, Rury R. Holman, Adrian F. Hernandez, Robert J. Mentz, Manesh R. Patel, W. Schuyler Jones
Diab Med. 2021;38:e14552. Published:Oct-2021. Epub:10-Mar-2021. PMID:33690915. doi:10.1111/dme.14552

Predicting the Risk of Developing Type 2 diabetes in Chinese People who have Coronary Heart Disease and Impaired Glucose Tolerance
Shishi Xu, Charles A. B. Scott, Ruth L. Coleman, Jaakko Tuomilehto, Rury R. Holman
Journal of Diabetes 2021;13:817-826. Published:Oct-2021. Epub:04-Mar-2021. PMID:33665904. doi:10.1111/1753-0407.13175

Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis
The Blood Pressure Lowering Treatment Trialists’ Collaboration
Lancet 2021;398:1053-64. Published:18-Sep-2021. Epub:27-Aug-2021. PMID:34461040. doi:10.1016/S0140-6736(21)01921-8

Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus
Carlos E Barbery, Anna Giczewska, Jennifer White, Yuliya Lokhnygina, Robert John Mentz, Rury R Holman, Neha Pagidipati, Adrian F Hernandez, W Schuyler Jones
Am Heart J. 2021;239:59-63. Published:Sep-2021. Epub:24-Apr-2021. PMID:33905751. doi:10.1016/j.ahj.2021.03.013

Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
Moritz J. Hundertmark, Olorunsola F. Agbaje, Ruth Coleman, Jyothis T. George, Rolf Grempler, Rury R. Holman, Hanan Lamlum, Jisoo Lee, Joanne E. Milton, Heiko G. Niessen, Oliver Rider, Christopher T. Rodgers, Ladislav Valkovic, Eleanor Wicks, Masliza Mahmod and Stefan Neubauer
ESC Heart Failure 2021;8:2580-2590. Published:Aug-2021. Epub:06-May-2021. PMID:33960149. doi:10.1002/ehf2.13406

Increased Risk of Incident Heart Failure and Death is Associated with Insulin Resistance in People with Newly- Diagnosed Type 2 Diabetes: UKPDS 89
Malgorzata Wamil, Ruth L. Coleman, Amanda I. Adler, John McMurray, Rury R. Holman
Diabetes Care 2021;44:1-8. Published:Aug-2021. PMID:341626. doi:10.2337/dc21-0429

Neck circumference and waist circumference associated with cardiovascular events in type 2 diabetes (Beijing Community Diabetes Study 23)
Guang Ran Yang, Ming Xia Yuan, Gang Wan, Xue Lian Zhang, Han Jing Fu, Shen Yuan Yuan, Liang Xiang Zhu, Rong Rong Xie, JianDong Zhang, Yu Ling Li, Yan Hua Sun, Qin Fang Dai, Da Yong Gao, Xue Li Cui, Jian Qin Gao, Zi Ming Wang, Ying Jun Chen, Yong Jin Li, Dong Ming Hu, Juan Gao, Ying Gao, Jie Miao, Yu Jie Chen & Rury. R. Holman
Sci Rep. 2021;11:9491. Published:04-May-2021. PMID:33947884. doi:10.1038/s41598-021-88927-9

Cardiovascular and renal safety of metformin in patients with diabetes and moderate-to-severe chronic kidney disease: observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials
Lindsay E. Clegg, Yankang Jing, R. Chris Penland, David W. Boulton, Adrian F. Hernandez, Rury R. Holman, Jiten Vora
Diabetes Obes Metab. 2021;23:1101-1110. Published:May-2021. Epub:04-Jan-2021. PMID:33394543. doi:10.1111/dom.14313

Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis.
Copland E, Canoy D, Nazarzadeh M, Bidel Z, Ramakrishnan R, Woodward M, Chalmers J, Teo KK, Pepine CJ, Davis BR, Kjeldsen S, Sundström J, Rahimi K; Blood Pressure Lowering Treatment Trialists' Collaboration
Lancet Oncol. 2021;558-570. Published:Apr-2021. PMID:33794209. doi:10.1016/S1470-2045(21)00033-4

NICE Guidance on Dapagliflozin for Treating Chronic Heart Failure with Reduced Ejection Fraction
Amanda Adler, Emma Douch, Lorna Dunning, Nicole Elliot
Lancet Diabetes Endocrinol 2021;9:261-263. Epub:10-Mar-2021. doi:10.1016/S2213-8587(21)00072-3

NICE guidance on caplacizumab for treating acute acquired thrombotic thrombocytopenia purpura
Mary Hughes, Carl Prescott, Nicole Elliott, Amanda I Adler
Lancet Haemology 2021;1:E14-E15. Epub:01-Jan-2021. doi:10.1016/S2352-3026(20)30406-3

Adjusting for Nonadherence or Stopping Treatments in Randomized Clinical Trials
Amanda I. Adler, Nicholas R. Latimer
JAMA 2021;20:2110-2111. doi:10.1001/jama.2021.2433

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis
Blood Pressure Lowering Treatment Trialists' Collaboration
Lancet 2021;397:1625-1636. PMID:33933205. doi:10.1016/S0140-6736(21)00590-0

The STEP 1 trial for weight loss: a step change in treating obesity?
Adler AI
Nat Med 2021;27:589-590. doi:10.1038/s41591-021-01319-4

Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis
Milad Nazarzadeh, Zeinab Bidel, Dexter Canoy, Emma Copland, Malgorzata Wamil, Jeannette Majert, Karl Smith Byrne, Johan Sundström, Koon Teo, Barry R Davis, John Chalmers, Carl J Pepine, Abbas Dehghan, Derrick A Bennett, George Davey Smith, Kazem Rahimi, on behalf of the Blood Pressure Lowering Treatment Trialists’ Collaboration*
Lancet 2021;398:1803-10. PMID:34774144. doi:10.1016/S0140-6736(21)01920-6

Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis
Ana-Catarina Pinho-Gomes, Luis Azevedo, Emma Copland, Dexter Canoy, Milad Nazarzadeh, Rema Ramakrishnan, Eivind Berge, Johan Sundström, Dipak Kotecha, Mark Woodward, Koon Teo, Barry R Davis, John Chalmers, Carl J Pepine, Kazem Rahimi, Blood Pressure Lowering Treatment Trialists’ Collaboration
PloS Med. 2021;18:e1003599. Published:--. PMID:34061831. doi:10.1371/journal.pmed.1003599

Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension: A Systematic Review and Individual Participant-based Meta-analysis
Stephen P Juraschek, Jiun-Ruey Hu, Jennifer L Cluett, Anthony Ishak, Carol Mita, Lewis A. Lipsitz, Nigel Beckett, Ruth L. Coleman, William Cushman, Greg Grandits, Rury R. Holman, Edgar R Miller 3rd, James Neaton, Ruth Peters, Jan A. Staessen, Lutgarde Thijs, Kenneth J Mukamal
Ann Int Med. 2020;174:58-68. Published:Jan-2021. Epub:10-Sep-2020. PMID:32909814. doi:10.7326/M20-4298

TriMaster: Randomised Double-Blind Crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as third line therapy in patients with Type 2 diabetes who have suboptimal glycaemic control on dual therapy with metformin with or without a sulfonylurea - a MASTERMIND study protocol
Catherine Angwin, Caroline Jenkinson, Angus Jones, Christopher Jennison, William Henley, Andrew Farmer, Naveed Sattar, Rury R Holman, Ewan Pearson, Beverley Shields, Andrew Hattersley , MASTERMIND consortium
BMJ Open 2020;10:e042784. Published:21-Dec-2020. PMID:33371044. doi:10.1136/bmjopen-2020-042784

The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Juliana CN Chan, Lee-Ling Lim, Nicholas J Wareham, Jonathan E Shaw, Trevor J Orchard, Ping Zhang, Eric SH Lau, Bjorn Eliasson, Alice PS Kong, Majid Ezzati, Carlos A Aguilar-Salinas, Margaret McGill, Naomi S Levitt, Guang Ning, Wing-Yee So, Jean Adams, Paula Bracco, Nita G Forouhi, Gabriel A Gregory, Jingchuan Guo, Xinyang Hua, Emma L Klatman, Dianna J Magliano, Boon-Peng Ng, David Ogilvie, Jenna Panter, Meda Pavkov, Hui Shao, Nigel Unwin, Martin White, Constance Wou, Ronald CW Ma, Maria I Schmidt, Ambady Ramachandran, Yutaka Seino, Peter H Bennett, Brian Oldenburg, Juan José Gagliardino, Andrea OY Luk, Philip M Clarke, Graham D Ogle, Melanie J Davies, Rury R Holman, Edward W Gregg
Lancet 2020;396:2019-82. Published:19-Dec-2020. Epub:12-Nov-2020. PMID:33189186. doi:10.1016/S0140-6736(20)32374-6
[Slides]

Rury Holman: the science of diabetes and a life of trials
Watts G
Lancet 2020;396:1956. Published:19-Dec-2020. Epub:12-Nov-2020. PMID:33189183. doi:10.1016/S0140-6736(20)32380-1

Predicting Heart Failure Events in Patients with Coronary Heart Disease and Impaired Glucose Tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial
Malgorzata Wamil, John JV McMurray, Charlie AB Scott, Ruth L Coleman, Yihong Sun, Eberhard Standl, Lars Rydèn, Rury R Holman
Diabetes Res Clin Pract. 2020;170:108488. Published:Dec-2020. Epub:06-Oct-2020. PMID:33035598. doi:10.1016/j.diabres.2020.108488

Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial
Annemarie B. van der Aart-van der Beek, Lindsay E. Clegg, Robert C. Penland, David W. Boulton, C. David Sjöström, Robert J. Mentz, Rury R. Holman, Hiddo J L Heerspink
Diabetes Obes Metab. 2020;22:2493-2498. Published:Dec-2020. Epub:15-Sep-2020. PMID:32803900. doi:10.1111/dom.14175

Long-term glucose variability and risk of nephropathy complication in UKPDS, ACCORD and VADT trials
Jin J. Zhou, Ruth Coleman, Rury R. Holman, Peter Reaven
Diabetologia 2020;63:2482-2485. Published:Nov-2020. Epub:21-Sep-2020. PMID:32954444. doi:10.1007/s00125-020-05273-7

Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial
Finlay A McAlister, Yinggan Zheng, Cynthia M Westerhout, John B Buse, Eberhard Standl, Darren K McGuire, Frans Van de Werf, Jennifer B Green, Paul W Armstrong, Rury R Holman, TECOS Study Group
Eur J Heart Fail. 2020;22:2026-2034. Published:Nov-2020. Epub:04-Jul-2020. PMID:32621557. doi:10.1002/ejhf.1958

A Proof of Concept Study to Evaluate the Impact of an Established Telehealth Mood Monitoring System on Mood in Individuals with Type 2 Diabetes when Initiating an Injectable Therapy
Hermione Price, Olorunsola F. Agbaje, Jonathan Price, Guy M Goodwin, John Geddes, Rury R. Holman
J Diab Metab. 2020;11:1-7. Published:28-Oct-2020. doi:10.35248/2155-6156.20.11.857

Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II)
Ernesto Maddaloni, Luca D’Onofrio, Francesco Alessandri, Carmen Mignogna, Gaetano Leto, Giuseppe Pascarella, Ivano Mezzaroma, Miriam Lichtner, Paolo Pozzilli, Felice Eugenio Agrò, Monica Rocco, Francesco Pugliese, Andrea Lenzi, Rury R. Holman, Claudio Maria Mastroianni, Raffaella Buzzetti on behalf of CoViDiab Study Group
Cardiovasc Diabetol. 2020;19:164. Published:01-Oct-2020. PMID:33004045. doi:10.1186/s12933-020-01140-2

Economic evaluation of factorial trials: cost-utility analysis of the AFORRD 2x2x2 factorial trial of atorvastatin, omega-3 fish oil and action-planning
Helen A. Dakin, Andrew Farmer, Alastair M. Gray, Rury R. Holman
Value in Health 2020;23:1340-1348. Published:Oct-2020. Epub:18-Aug-2020. PMID:33032778. doi:10.1016/j.jval.2020.05.018

Risk of anemia with metformin use in type 2 diabetes: A MASTERMIND study
Louise A Donnelly, John M Dennis, Ruth L Coleman, Naveed Sattar, Andrew T Hattersley, Rury R Holman, Ewan R Pearson
Diabetes Care 2020;43:2493-2499. Published:Oct-2020. Epub:14-Aug-2020. PMID:32801130. doi:10.2337/dc20-1104

Benchmarking the Cost- Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data
Jose Leal, Shelby D Ree, Rishi Patel, Oliver Rivero-Arias, Yanhong Li, Kevin A Schulman, Robert M Califf, Rury R. Holman, Alastair Gray
Diabetes Care 2020;43:2485-2492. Published:Oct-2020. Epub:12-Aug-2020. PMID:32796009. doi:10.2337/dc20-0717

Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial
Hertzel C. Gerstein, Ruth L. Coleman, Charles A.B. Scott, Shishi Xu, Jaakko Tuomilehto, Lars Rydén, Rury R. Holman for the ACE Study Group
Diabetes Care 2020;43:2242-2247. Published:Sep-2020. Epub:08-Jul-2020. PMID:32641379. doi:10.2337/dc19-2046

Predicting Post One-year Durability of Glucose-lowering Monotherapies in Patients with Newly-diagnosed Type 2 Diabetes Mellitus - A MASTERMIND Precision Medicine Approach (UKPDS 87)
Olorunsola F. Agbaje, Ruth L. Coleman, Andrew T. Hattersley, Angus G. Jones, Ewan R. Pearson, Beverley M. Shields, and Rury R. Holman, for the MASTERMIND consortium
Diabetes Res Clin Pract. 2020;166:108333. Published:Aug-2020. Epub:20-Jul-2020. PMID:32702468. doi:10.1016/j.diabres.2020.108333

Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans
Laurie L. Baggio, Elodie M. Varin, Jacqueline A. Koehler, Yuliya Lokhnygina, Susanna Stevens, Rury R. Holman, and Daniel J. Drucker
Nat Commun. 2020;11:3766. Published:28-Jul-2020. PMID:32724076. doi:10.1038/s41467-020-17556-z

Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients
Chitrabhanu Ballav, Archana Dhere, Irene Kennedy, Olorunsola F. Agbaje, Sarah White, Rachel Franklin, Bolette Hartmann, Jens J. Holst, Rury R. Holman, Katharine R. Owen
Endocrinol Diab Metab. 2020;3:e00130. Published:Jul-2020. Epub:12-Jun-2020. PMID:327045. doi:10.1002/edm2.130

Can the Cardiovascular Risk Reductions Observed with Empagliflozin in the EMPA-REG OUTCOME Trial be Explained by the Changes Seen in Conventional Cardiovascular Risk Factor Levels?
Ruth L. Coleman, Alastair M. Gray, Uli C. Broedl, David Fitchett, Jyothis T George, Hans-Juergen Woerle, Bernard Zinman, and Rury R. Holman
Diabetes Obes Metab. 2020;22:1151-1156. Published:Jul-2020. Epub:01-Mar-2020. PMID:32115840. doi:10.1111/dom.14017

Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
Andrew P McGovern, Michael Hogg, Beverley M Shields, Naveed Sattar, Rury R Holman, Ewan R Pearson, Andrew T Hattersley, Angus G Jones, John M Dennis
BMJ Open Diabetes Res Care. 2020;8:e001238. Published:24-May-2020. PMID:32448787. doi:10.1136/bmjdrc-2020-001238

Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data
Helen A. Dakin, José Leal, Andrew Briggs, Philip Clarke, Rury R. Holman, Alastair Gray
Med Decis Making. 2020;40:460-473. Published:May-2020. Epub:20-May-2020. PMID:32431211. doi:10.1177/0272989X20916442

β-cell secretory dysfunction: a key cause of type 2 diabetes
Rury R. Holman, Anne Clarke, Patrik Rorsman
Lancet Diabetes Endocrinol 2020;8:370. Published:May-2020. PMID:32333873. doi:10.1016/S2213-8587(20)30119-4

Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes
M. Angelyn Bethel, Susanna R. Stevens, John B. Buse, Jasmine Choi, Stephanie M. Gustavson, Nayyar Iqbal, Yuliya Lokhnygina, Robert J. Mentz, Rishi A. Patel, Peter Öhman, Guntram Schernthaner, Albert LeCube, Adrian F. Hernandez, Rury R. Holman
Circulation 2020;141:1360-1370. Published:28-Apr-2020. Epub:26-Feb-2020. PMID:32098501. doi:10.1161/CIRCULATIONAHA.119.043353

Improved Framingham Risk Scores of Patients with Type 2 Diabetes Mellitus in the Beijing Community: A 10-Year Prospective Study of the Effects of Multifactorial Interventions on Cardiovascular Risk Factors (The Beijing Communities Diabetes Study 22)
Xue-Lian Zhang, Gang Wan, Ming-Xia Yuan, Guang-Ran Yang, Han-Jing Fu, Liang-Xiang Zhu, Rong-Rong Xie, Yu-Jie Lv, Jian-Dong Zhang, Yu-Ling Li, Qin-Fang Dai, Yu Ji, Rury R. Holman, Shen-Yuan Yuan on behalf of Beijing Communities Diabetes Study Group
Diabetes Ther 2020;11:885-903. Published:Apr-2020. Epub:21-Feb-2020. PMID:32086768. doi:10.1007/s13300-020-00782-5

Impact of Regulatory Guidance on Evaluating Cardiovascular Risk in New Glucose-Lowering Drugs to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions
Abhinav Sharma, Neha J. Pagidipati, Robert M. Califf, Darren K. McGuire, Jennifer B. Green, Dave Demets, Mehul Desai, Peter M. DiBattiste, Jyothis Thomas George, Hertzel C. Gerstein, Todd Hobbs, Rury R. Holman, Francesca C. Lawson, Lawrence A. Leiter, Marc A. Pfeffer, Jane Reusch, Jeffrey S. Riesmeyer, Yves Rosenberg, Robert Temple, Stephen Wiviott, John McMurray, Christopher Granger
Circulation 2020;141:843-862. Published:10-Mar-2020. Epub:29-Jan-2020. PMID:31992065. doi:10.1161/CIRCULATIONAHA.119.041022

Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86)
Ernesto Maddaloni, Ruth L. Coleman, Olorunsola F. Agbaje, Raffaella Buzzetti, Rury R. Holman
Lancet Diabetes Endocrinol 2020;8:206-15. Published:Mar-2020. Epub:04-Feb-2020. PMID:32032540. doi:10.1016/S2213-8587(20)30003-6

Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights from EXSCEL
Eberhard Standl, Susanna R. Stevens, Yuliya Lokhnygina, Angelyn Bethel, John B. Buse, Stephanie M. Gustavson, Aldo P. Maggioni, Robert J. Mentz, Adrian F. Hernandez, Rury R. Holman, for the EXSCEL Study Group
Diabetes Care 2020;43:643-652. Published:Mar-2020. Epub:27-Dec-2019. PMID:31882409. doi:10.2337/dc19-1079

Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Shelby D. Reed, Yanhong Li, Helen A. Dakin, Frauke Becker, Jose Leal, Stephanie M. Gustavson, Bernt Kartman, Eric Wittbrodt, Robert J. Mentz, Neha J. Pagidipati, M. Angelyn Bethel, Alastair M. Gray, Rury R. Holman, Adrian F. Hernandez, for the EXSCEL Study Group
Diabetes Care 2020;43:374-381. Published:Feb-2020. Epub:05-Dec-2019. PMID:31806653. doi:10.2337/dc19-0950

Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS
Gaetano M. De Ferrari, Susanna R. Stevens, Giuseppe Ambrosio, Sergio Leonardi, Darren K. McGuire, Paul W. Armstrong, Jennifer B. Green, Malgorzata Wamil, Rury R. Holman, Eric D. Peterson; on behalf of the TECOS Study Group
Am Heart J 2020;220:82-88. Published:Feb-2020. Epub:04-Dec-2019. PMID:31790905. doi:10.1016/j.ahj.2019.11.005

Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial
M. Angelyn Bethel, Robert J. Mentz, Peter Merrill, John B. Buse, Juliana C. Chan, Shaun G. Goodman, Nayyar Iqbal, Neli Jakuboniene, Brian Katona, Yuliya Lokhnygina, Renato D. Lopes, Aldo P. Maggioni, Peter Ohman, Tsvetalina Tankova, George L. Bakris, Adrian F. Hernandez, and Rury R. Holman
Diabetes Care 2020;43:446-452. Published:Feb-2020. Epub:22-Nov-2019. PMID:31757838. doi:10.2337/dc19-1065

Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS
Neha J. Pagidipati, Yinggan Zheng, Jennifer B. Green, Darren K. McGuire, Robert J. Mentz, Svati Shah, Pablo Aschner, Tuncay Delibasi, Helena W. Rodbard, Cynthia M. Westerhout, Rury R. Holman, Eric D. Peterson, on behalf of the TECOS Study Group
Am Heart J 2020;219:47-57. Published:Jan-2020. Epub:20-Oct-2019. PMID:31707324. doi:10.1016/j.ahj.2019.09.016

USA stockpiling of remdesivir: How should the world respond?
Dalia Dawoud, Kalipso Chalkidou, Richard Sullivan, Francis J Ruiz, Amanda Adler
Journal of Comparative Effective Research 2020;9:1243-1246. Epub:04-Dec-2020. PMID:33274643. doi:10.2217/cer-2020-0174

Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL
Idzerda NMA, Clegg LE, Hernandez AF, Bakris G, Penland RC, Boulton DW, Bethel MA, Holman RR, Heerspink HJL
Diabetes Obes Metab. 2020;22:798-806. Epub:07-Jan-2020. PMID:31912603. doi:10.1111/dom.13958

Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; protocol for a randomised, placebo-controlled prophylaxis study (COPCOV)
Schilling W, Callery J, Taylor W, Mukaka M, Ekkapongpisit M, Watson J, Chandna A, Panapipat S, Tubprasert J, Yuentrakul P, Waithira N, Cope T, Dhorda M, Cruz C, von Seidlein L, Milton J, LLewelyn M, Adler A, Chotivanich K, Cheah PY ... [Show all 26] ... White N
Wellcome Open Research 2020;5:20. doi:10.12688/wellcomeopenres.15784.1

Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial
Badjatiya A, Merrill P, Buse JB, Goodman SG, Katona B, Iqbal N, Pagidipati NJ, Sattar N, Holman RR, Hernandez AF, Mentz RJ, Patel MR, Jones WS
Circ Cardiovasc Interv. 2019;12:e008018. Published:Dec-2019. Epub:22-Nov-2019. PMID:31752517. doi:10.1161/CIRCINTERVENTIONS.119.008018

Associations between beta-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease
Jay S. Shavadia, Yinggan Zheng, Jennifer B. Green, Paul W. Armstrong, Cynthia M. Westerhout, Darren K. McGuire, Jan H. Cornel, Rury R. Holman, Eric D. Peterson
Am Heart J 2019;218:92-99. Published:Dec-2019. Epub:20-Oct-2019. PMID:31715435. doi:10.1016/j.ahj.2019.09.013

International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS
Ankeet S. Bhatt, Nancy Luo, Nicole Solomon, Neha J. Pagidipati, Giuseppe Ambrosio, Jennifer B. Green, Darren K. McGuire, Eberhard Standl, Jan H Cornel, Sigrun Halvorsen, Renato D. Lopes, Harvey D. White, Rury R. Holman, Eric D. Peterson, Robert J. Mentz, on behalf of the TECOS Study Group
Am Heart J 2019;218:57-65. Published:Dec-2019. Epub:28-Aug-2019. PMID:31707329. doi:10.1016/j.ahj.2019.08.016

Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial
Fudim M, White J, Pagidipati NJ, Lokhnygina Y, Wainstein J, Murin J, Iqbal N, Öhman P, Lopes RD, Reicher B, Holman RR, Hernandez AF, Mentz RJ
Circulation 2019;140:1613-1622. Published:12-Nov-2019. Epub:23-Sep-2019. PMID:31542942. doi:10.1161/CIRCULATIONAHA.119.041659

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
Clegg LE, Penland RC, Bachina S, Boulton DW, Thuresson M, Heerspink HJL, Gustavson S, Sjöström CD, Ruggles JA, Hernandez AF, Buse JB, Mentz RJ, Holman RR.
Cardiovasc Diabetol 2019;18:138. Published:22-Oct-2019. PMID:31640705. doi:10.1186/s12933-019-0942-x

Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes
Ruth L. Coleman, Charles A. B. Scott, Zhihui Lang, M. Angelyn Bethel, Jaakko Tuomilehto and Rury R. Holman
Cardiovasc Diabetol 2019;18:135. Published:17-Oct-2019. PMID:31623625. doi:10.1186/s12933-019-0933-y

A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health
Ahmad Moolla, Kenzo Motohashi, Tom Marjot, Amelia Shard, Mark Ainsworth, Alastair Gray, Rury Holman, Michael Pavlides, John D Ryan, Jeremy W Tomlinson, Jeremy F Cobbold
Frontline Gastroenterology 2019;10:337–346. Published:Oct-2019. Epub:30-Apr-2019. PMID:31682643. doi:10.1136/flgastro-2018-101155

Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS
Michael A. Nauck, Darren K. McGuire, Karen S. Pieper, Yuliya Lokhnygina, Timo E. Strandberg, Axel Riefflin, Tuncay Delibasi, Eric D. Peterson, Harvey D. White, Russell Scott and Rury R. Holman
Cardiovasc Diabetol 2019;18:116. Published:03-Sep-2019. PMID:31481069. doi:10.1186/s12933-019-0921-2

The importance of randomised vs non-randomised trials - Authors' reply
Gerstein HC, McMurray J, Holman RR
Lancet 2019;394:635. Published:24-Aug-2019. PMID:31448734. doi:10.1016/S0140-6736(19)31111-0

Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes
Patrícia O. Guimarães, Eric D. Peterson, Susanna R. Stevens, Yuliya Lokhnygina, Jennifer B. Green, Darren K. McGuire, Rury R. Holman, Renato D. Lopes
Int J Cardiol. 2019;289:58-62. Published:15-Aug-2019. Epub:30-Apr-2019. PMID:31079973. doi:10.1016/j.ijcard.2019.04.085

Comment on Kim et al. The Effect of a Smartphone-Based, Patient-Centered Diabetes Care System in Patients With Type 2 Diabetes: A Randomized, Controlled Trial for 24 Weeks. Diabetes Care 2019;42:3-9
Xiqian Huo, Rury R. Holman, Jane Armitage
Diabetes Care 2019;42:e125. Published:Jul-2019. PMID:31221710. doi:10.2337/dc19-0535

Time trends in prescribing of type 2 diabetes drugs, glycemic response and risk factors: a retrospective analysis of primary care data, 2010-2017
John M Dennis, William E Henley, Andrew P McGovern, Andrew J Farmer, N Sattar, Rury R Holman, Ewan R Pearson, Andrew T Hattersley, Beverley M Shields, Angus G Jones on behalf of the MASTERMIND consortium
Diabetes Obes Metab 2019;21:1576-1584. Published:13-Jun-2019. Epub:03-Mar-2019. PMID:30828962. doi:10.1111/dom.13687

Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
M. Angelyn Bethel, Rishi A Patel, Brian G. Katona, Vivian P. Thompson, Stephanie M. Gustavson, Peter Ohman, Nayyar Iqbal John B. Buse, Rury R. Holman; for the EXSCEL Study Group
Diabetes Care 2019;42 :1075-1080. Published:Jun-2019. Epub:22-Apr-2019. PMID:31010875. doi:10.2337/dc18-2028

Diabetes Care Editors' Expert Forum 2018: Managing Big Data for Diabetes Research and Care
Riddle MC, Blonde L, Gerstein HC, Gregg EW, Holman RR, Lachin JM, Nichols GA, Turchin A, Cefalu WT
Diabetes Care 2019;42:1136-1146. Published:Jun-2019. PMID:31666233. doi:10.2337/dci19-0020

Comment on Davis et al. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. Diabetes Care 2019;42:157-163
Eberhard Standl, Jennifer B. Green, Rury R. Holman
Diabetes Care 2019;42:e95. Published:Jun-2019. PMID:31110121. doi:10.2337/dc18-2597

Investigating the stratified efficacy and safety of pharmacological blood pressure lowering: A protocol for individual patient-level data meta-analyses of over 300,000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC)
Kazem Rahimi, Dexter Canoy, Milad Nazarzadeh, Gholamreza Salimi-Khorshidi, Mark Woodward, Koon Teo, Barry R Davis, John Chalmers, Carl J Pepine, on behalf of the Blood Pressure Lowering Treatment Trialists’ Collaboration
BMJ Open 2019;9:e028698. Published:22-May-2019. PMID:31123005. doi:10.1136/bmjopen-2018-028698

An Outcome Model Approach to Generalizing Randomized Controlled Trial Results to a Target Population
Benjamin A. Goldstein, Matthew Phelan, Neha J. Pagidipati, Rury R. Holman, Michael J. Pencina, Elizabeth A. Stuart
J Am Med Inform Assoc. 2019;5:429–437. Published:May-2019. Epub:14-Mar-2019. PMID:30869798. doi:10.1093/jamia/ocy188

What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch or continue? A MASTERMIND study
Andrew P. McGovern, John M. Dennis, Beverley M. Shields, Andrew T. Hattersley, Ewan R. Pearson, Angus G. Jones and on behalf of the MASTERMIND Consortium
BMC Medicine 2019;17:79. Published:12-Apr-2019. PMID:30979373. doi:10.1186/s12916-019-1307-8

Comparison of Nine Platelet Function Tests Used to Determine Responses to Different Aspirin Dosages in People with Type 2 Diabetes
Paul Harrison, M. Angelyn Bethel, Irene Kennedy, Robert Dinsdale, Ruth Coleman, Rury R. Holman
Platelets 2019;30:521-529. Published:Apr-2019. Epub:09-Jul-2018. PMID:29985735. doi:10.1080/09537104.2018.1478402

Effect of acarbose on cardiovascular events and new-onset diabetes in patients with coronary heart disease and impaired glucose tolerance
Yidong Wei, Wen Xu
Future Cardiology 2019;15:127-133. Published:Mar-2019. Epub:22-Feb-2019. PMID:30793928. doi:10.2217/fca-2018-0062

Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL
Lindsay E. Clegg, Hiddo J.L. Heerspink, Robert C. Penland, Weifeng Tang, David W. Boulton, Srinivas Bachina, Robert D. Fox, Peter Fenici Marcus Thuresson, Robert J. Mentz, Adrian F. Hernandez, and Rury R. Holman
Diabetes Care 2019;42:318-326. Published:Feb-2019. Epub:06-Dec-2018. PMID:30523029. doi:10.2337/dc18-1871

Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9,259 Deaths in 9 Trials
Alexander C Fanaroff, Robert Clare, Karen S Pieper, Kenneth W Mahaffey, Chiara Melloni, Jennifer Green John H. Alexander, W. Schuyler Jones, Robert W. Harrison, Rajendra H Mehta, Thomas J. Povsic, Humberto G. Moreira, Sana M. Al-Khatib, Matthew T. Roe, David F Kong, Robin Mathews, Pierluigi Tricoci, Rury R. Holman, Lars Wallentin, Claes Held , Robert McKinnon Califf, Karen P. Alexander, and Renato D Lopes
Circulation 2019;139:863-873. Published:Feb-2019. Epub:28-Nov-2018. PMID:30586739. doi:10.1161/CIRCULATIONAHA.118.037202

Real-world studies no substitute for RCTs in establishing efficacy
Hertzel C Gerstein, John McMurray, Rury R Holman
Lancet 2019;293:210-11. Published:19-Jan-2019. PMID:30663582. doi:10.1016/S0140-6736(18)32840-X

Progression of glucose-lowering diabetes therapy in TECOS
M. Angelyn Bethel, Samuel S. Engel, Susanna R. Stevens, Yuliya Lokhnygina, Jie Ding, Robert G. Josse, Michael Alvarsson, Irene Hramiak, Jennifer B. Green, Eric D. Peterson, Rury R. Holman
Endocrinol Diab Metab 2019;2:e00053. Published:13-Jan-2019. Epub:23-Dec-2018. PMID:30815579. doi:10.1002/edm2.53

Effects of blood pressure lowering on cardiovascular events, in the context of regression to the mean: a systematic review of randomized trials.
Salam A, Atkins E, Sundström J, Hirakawa Y, Ettehad D, Emdin C, Neal B, Woodward M, Chalmers J, Berge E, Yusuf S, Rahimi K, Rodgers A; Blood Pressure Lowering Treatment Trialists’ Collaboration
J Hypertens 2019;37:16-23. Published:01-Jan-2019. PMID:30499920. doi:10.1097/HJH.0000000000001994

Simulating the impact of targeting lower systolic blood pressure and LDL-cholesterol levels on type 2 diabetes complication rates
Mostafa SA, Coleman RL, Agbaje OF, Gray A, Holman RR, Bethel MA
J Diabetes Complications 2019;33:69-74. Published:Jan-2019. Epub:10-Oct-2018. PMID:30361000. doi:10.1016/j.jdiacomp.2018.09.017

Testing for qualitative heterogeneity: An application to composite endpoints in survival analysis
Abderrahim Oulhaj, Anouar El Ghouch and Rury R Holman
Stat Methods Med Res. 2019;28:151-169. Published:Jan-2019. Epub:03-Jul-2017. PMID:28670972. doi:10.1177/0962280217717761

Long-term Risk of Cardiovascular Disease in Individuals with Latent Autoimmune Diabetes of Adults (UKPDS 85)
E. Maddaloni, R.L.Coleman, P.Pozzilli, R.R. Holman
Diabetes Obese Metab. 2019;2019:2115-2122. Epub:17-May-2019. PMID:31099472. doi:10.1111/dom.13788

Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients with Preexisting Cardiovascular Disease: A Prespecified Analysis From EXSCEL
Robert J Mentz, Vivian P. Thompson, David Aguilar, Jasmine Choi, Stephanie M. Gustavson, Nayyar Iqbal, Alice P. S. Kong, Peter Öhman, Naveed Sattar, Russell S Scott, Yee Weng Wong, Rury R. Holman, and Adrian F. Hernandez
Circulation 2018;138:2576-2578. Published:27-Nov-2018. Epub:28-Aug-2018. PMID:30571356. doi:10.1161/CIRCULATIONAHA.118.036811

Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial
Robert J. Mentz, M. Angelyn Bethel, Peter Merrill, Yuliya Lokhnygina, John B. Buse, Juliana C. Chan, João S. Felício, Shaun G. Goodman, Jasmine Choi, Stephanie M. Gustavson, Nayyar Iqbal, Renato D. Lopes, Aldo P. Maggioni, Peter Öhman, Neha J. Pagidipati, Neil R. Poulter, Ambady Ramachandran, Barry Reicher, Rury R. Holman, Adrian F. Hernandez, on behalf of the EXSCEL Study Group
J Am Heart Assoc 2018;7:e009304.. Published:02-Oct-2018. Epub:20-Sep-2018. PMID:30371301. doi:10.1161/JAHA.118.009304

Metformin – 60 years of clinical experience (Chinese edition)
Ed. Ian W Campbell, Harry CS Howlett, Rury R Holman, Clifford J Bailey
ISBN 978-7-5478-4154-9 2018;1-122. Published:01-Sep-2018

Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data.
Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones AG, Hamilton WT, Sattar N, Janmohamed S, Holman RR, Pearson ER, Shields BM, Hattersley AT; MASTERMIND Consortium.
Diabetes Care 2018;41:1844–1853. Published:Sep-2018. Epub:02-Aug-2018. PMID:30072404. doi:10.2337/dc18-0344

What does the ACE trial tell us? – Commentary
Rury R. Holman
Journal of Diabetes 2018;10:683-685. Published:Aug-2018. Epub:17-May-2018. PMID:29774661. doi:10.1111/1753-0407.12770

Relationship between Baseline Physical Activity Assessed by Pedometer Count and New-onset Diabetes in the NAVIGATOR Trial
William E. Kraus, Thomas Yates, Jaakko Tuomilehto, Jie-Lena Sun, Laine Thomas, John J.V. McMurray, M. Angelyn Bethel, Steven M. Haffner, Rury R. Holman
BMJ Open Diabetes Research & Care 2018;6:e000523. Published:19-Jul-2018. PMID:30073088. doi:10.1136/bmjdrc-2018-000523

Genetic Variants in CPA6 and PRPF31 are Associated with Variation in Response to Metformin in Individuals with Type 2 Diabetes
Rotroff DM, Yee SW, Zhou K, Marvel SW, Shah HS, Jack JR, Havener TM, Hedderson MM, Kubo M, Herman MA, Gao H, Mychaleckyi JC, McLeod HL, Doria A, Giacomini KM, Pearson ER, Wagner MJ, Buse JB, Motsinger-Reif AA; MetGen Investigators and the ACCORD/ACCORDion Investigators.
Diabetes 2018;67:1428-1440. Published:Jul-2018. Epub:12-Apr-2018. PMID:29650774. doi:10.2337/db17-1164

Longitudinal Medical Resources and Costs Among Type 2 Diabetes Patients Participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
Reed SD, Li Y, Leal J, Graham F, Radican L, Adler A, Alfredsson J, Buse JB, Green JB, Kaufman KD, Riefflin A, Van de Werf F, Peterson ED, Gray AM, Holman RR, TECOS Study Group
Diabetes Obes Metab 2018;20:1732-1739. Published:Jul-2018. Epub:23-Mar-2018. PMID:29573215. doi:10.1111/dom.13292

Aspects of Multicomponent Integrated Care Promote Sustained Improvement in Surrogate Clinical Outcomes: A Systematic Review and Meta-analysis
Lee-Ling Lim, Eric S.H. Lau, Alice P.S. Kong, Melanie J. Davies, Naomi S. Levitt, Björn Eliasson, Carlos A. Aguilar-Salinas, Guang Ning, Yutaka Seino, Wing-Yee So, Margaret McGill, Graham D. Ogle, Trevor J. Orchard, Philip Clarke, Rury R. Holman, Edward W. Gregg, Juan José Gagliardino, Juliana C.N. Chan
Diabetes Care 2018;41:1312-1320. Published:Jun-2018. PMID:29784698. doi:10.2337/dc17-2010

A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks
Matthew C. Riddle, Hertzel C. Gerstein, Rury R. Holman, Silvio Inzucchi, Bernard Zinman, Sophia Zoungas, and William T. Cefalu
Diabetes Care 2018;41:1121-1124. Published:Jun-2018. PMID:29784695. doi:10.2337/dci18-0018

Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT
Simon J Griffin, M Angelyn Bethel, Rury R Holman, Kamlesh Khunti, Nicholas Wareham, Gwen Brierley, Melanie Davies, Andrew Dymond, Rose Eichenberger, Philip Evans, Alastair Gray, Colin Greaves, Kyla Harrington, Graham Hitman, Greg Irving, Sarah Lessels, Ann Millward, John R Petrie, Martin Rutter, Mike Sampson, Naveed Sattar and Stephen Sharp
Health Technology Assessment 2018;22:1-64. Published:Apr-2018. PMID:29652246. doi:10.3310/hta22180

Class Effect for SGLT2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist
Bethel MA, McMurray JJV
Circulation 2018;137:1218-1220. Published:20-Mar-2018. PMID:29555706. doi:10.1161/CIRCULATIONAHA.117.030117

Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data
Kunal N. Karmali, Donald M. Lloyd-Jones, Joep van der Leeuw, David C. Goff, Jr., Salim Yusuf, Alberto Zanchetti, Paul Glasziou, Rodney Jackson, Mark Woodward, Anthony Rodgers, Bruce C. Neal, Eivind Berge, Koon Teo, Barry R. Davis, John Chalmers, Carl Pepine, Kazem Rahimi, Johan SundstroÈm, on behalf of the Blood Pressure Lowering Treatment Trialists' Collaboration
PloS Med 2018;15:e100253. Published:20-Mar-2018. PMID:29558462. doi:10.1371/journal.pmed.1002538

Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype
Eberhard Standl, Susanna R. Stevens, Paul W. Armstrong, John B. Buse, Juliana C.N. Chan, Jennifer B. Green, John M. Lachin, Andre Scheen, Florence Travert, Frans Van de Werf, Eric D. Peterson, and Rury R. Holman, on behalf of the TECOS Study Group
Diabetes Care 2018;41:596-603. Published:Mar-2018. Epub:08-Jan-2018. PMID:29311155. doi:10.2337/dc17-1778

Management of T2DM in 2017: Clinically relevant results from cardiovascular outcome trials
Rury R Holman
Nature Reviews Endocrinology 2018;14:67-68. Published:Feb-2018. Epub:05-Jan-2018. PMID:29302077. doi:10.1038/nrendo.2017.179

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
M. Angelyn Bethel, Rishi A. Patel, Peter Merrill, Yuliya Lokhnygina, John B. Buse, Robert J. Mentz, Neha J. Pagidipati, Juliana C. Chan, Stephanie M. Gustavson, Nayyar Iqbal, Aldo P. Maggioni, Peter Öhman, Neil R. Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F. Hernandez, and Rury R. Holman, for the EXSCEL Study Group
Lancet Diabetes Endocrinol. 2018;6:105-113. Published:Feb-2018. Epub:06-Dec-2017. PMID:29221659. doi:10.1016/S2213-8587(17)30412-6
[Slides]

Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease
S. A. Mostafa, R. L. Coleman, O. F. Agbaje, A. M. Gray, R. R. Holman and M. A. Bethel
Diabet Med. 2018;35:72-77. Published:Jan-2018. Epub:23-Oct-2017. PMID:29057545. doi:10.1111/dme.13533

Cardiovascular Outcomes Trials in Type 2 Diabetes:Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum
William T. Cefalu, Sanjay Kaul, Hertzel C. Gerstein, Rury R. Holman, Bernard Zinman, Jay S. Skyler, Jennifer B. Green, John B. Buse, Silvio E. Inzucchi, Lawrence A. Leiter, Itamar Raz, Julio Rosenstock, and Matthew C. Riddle
Diabetes Care 2018;41:14-31. Published:Jan-2018. PMID:29263194. doi:10.2337/dci17-0057

Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS
Alfredsson J, Green JB, Stevens SR, Reed SD, Hramiak I, White H, Armstrong PW, Bethel MA, Engel SS, McGuire DK, Van de Werf F, Peterson ED, Holman RR, on Behalf of the TECOS Study Group
Diabetes Obes Metab. 2018;20:2379-2388. Epub:19-Jun-2018. PMID:29923323. doi:10.1111/dom.13377

Effect of race on the glycaemic response to sitagliptin. Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
Davis TME, Mulder H, Lokhnygina Y, Standl E, Aschner P, Chuang LM, Grado CR, Peterson ED, Holman RR
Diabetes, Obesity and Metabolism 2018;20:1427-1434. Epub:06-Feb-2018. PMID:29405540. doi:10.1111/dom.13242

Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long- Term Glycemic Response to DPP-4 Inhibitor Therapy
John M. Dennis, Beverley M. Shields, Anita V. Hill, Bridget A. Knight, Timothy J. McDonald, Lauren R. Rodgers, Michael N. Weedon, William E. Henley, Naveed Sattar, Rury R. Holman, Ewan R. Pearson, Andrew T. Hattersley, and Angus G. Jones, on behalf of the MASTERMIND consortium
Diabetes Care 2018;41:705-712. Epub:31-Jan-2018. PMID:29386249. doi:10.2337/dc17-1827

Baseline Characteristics and Temporal Differences in Acarbose Cardiovascular Evaluation (ACE) Trial Participants
Michael J. Theodorakis, Ruth L. Coleman, Huimei Feng, Juliana Chan, Jean-Louis Chiasson, Junbo Ge, Hertzel C. Gerstein, Yong Huo, Zhihui Lang, John J. McMurray, Lars Rydén, Stefan Schröder, Michal Tendera, Jaakko Tuomilehto, Wenying Yang, Dayi Hu, Changyu Pan and Rury R. Holman for the ACE Study Group
Am Heart J 2017;199:170-175. Published:May-2018. Epub:10-Sep-2017. PMID:29754657. doi:10.1016/j.ahj.2017.09.001

Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes – Authors' reply
Rury R. Holman, M. Angelyn Bethel, Adrian F. Hernandez,
N Eng J Med 2017;377:2502. Published:21-Dec-2017. PMID:29262286. doi:10.1056/NEJMc1714163

Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial
Abhinav Sharma, Jennifer B. Green, Allison Dunning, Yuliya Lokhnygina, Sana M. Al-Khatib, Renato D. Lopes, John B. Buse, John M. Lachin, Frans Van de Werf, Paul W. Armstrong, Keith D. Kaufman, Eberhard Standl, Juliana C.N. Chan, Larry A. Distiller, Russell Scott, Eric D. Peterson, and Rury R. Holman, on behalf of the TECOS Study Group
Diabetes Care 2017;40:1763-1770. Published:Dec-2017. Epub:06-Oct-2017. PMID:28986504. doi:10.2337/dc17-1091

Health selection into neighborhoods among patients enrolled in a clinical trial
Mariana Arcaya, Ruth L. Coleman, Fahad Razak, Maria L. Alva, Rury R. Holman
Preventive Medicine Reports 2017;8:51–54. Published:Dec-2017. Epub:28-Jul-2017. PMID:28924547. doi:10.1016/j.pmedr.2017.07.003

Effects of Acarbose on Cardiovascular and Diabetes Outcomes in Patients with Coronary Heart Disease and Impaired Glucose Tolerance: A Randomised Controlled Trial
Rury R Holman, Ruth L Coleman, Juliana C N Chan, Jean-Louis Chiasson, Huimei Feng, Junbo Ge, Hertzel C Gerstein, Richard Gray, Yong Huo, Zhihui Lang, John J McMurray, Lars Rydén, Stefan Schröder, Yihong Sun, Michael J Theodorakis, Michal Tendera, Lynne Tucker, Jaakko Tuomilehto, Yidong Wei, Wenying Yang, Duolao Wang, Dayi Hu, Changyu Pan for the ACE Study Group
Lancet Diabetes Endocrinol. 2017;5:877-86. Published:Nov-2017. Epub:13-Sep-2017. PMID:28917545. doi:10.1016/S2213-8587(17)30309-1
[Slides] [Slides #2]
Erratum in :
Lancet Diabetes Endocrinol. 2019;5:PE5, Print:May-2019, Epub:01-May-2019, doi:10.1016/S2213-8587(19)30063-4

Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin
Navar AM, Gallup DS, Lokhnygina Y, Green JB, McGuire DK, Armstrong PW, Buse JB, Engel SS, Lachin JM, Standl E, Van de Werf F, Holman RR, Peterson ED
Hypertension 2017;70:907-914. Published:Nov-2017. Epub:28-Aug-2017. PMID:28847886. doi:10.1161/HYPERTENSIONAHA.117.09482

Safety of Sitagliptin in Patients with Type 2 Diabetes and Chronic Kidney Disease: Outcomes from TECOS
Engel SS, Suryawanshi S, Stevens SR, Josse RG, Cornel JH, Jakuboniene N, Riefflin A, Tankova T, Wainstein J, Peterson ED, Holman RR; TECOS Study Group
Diabetes Obes Metab. 2017;19:1587–1593. Published:Nov-2017. Epub:22-Apr-2017. PMID:28432745. doi:10.1111/dom.12983

Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis
Rakesh Malhotra, Hoang Anh Nguyen, Oscar Benavente, Mihriye Mete, Barbara Howard, Jonathan Mant, Michelle C. Odden, Carmen A. Peralta, Alfred Cheung, Girish Nadkarni, Ruth L. Coleman, Rury R. Holman, Alberto Zanchetti, Ruth Peters, Nigel Beckett, Jan Staessen, Joachim H. Ix
JAMA Intern Med 2017;177:1498-1505. Published:Oct-2017. Epub:05-Sep-2017. PMID:28873137. doi:10.1001/jamainternmed.2017.4377

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman, M. Angelyn Bethel, Robert J. Mentz, Vivian P. Thompson, Yuliya Lokhnygina, John B. Buse, Juliana C. Chan, Jasmine Choi, Stephanie M. Gustavson, Nayyar Iqbal, Aldo P. Maggioni, Steven P. Marso, Peter Öhman, Neha J. Pagidipati, Neil Poulter, Ambady Ramachandran, Bernard Zinman, and Adrian F. Hernandez, for the EXSCEL Study Group
N Engl J Med 2017;377:1228-39. Published:28-Sep-2017. Epub:14-Sep-2017. PMID:28910237. doi:10.1056/NEJMoa1612917
[Slides]

Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes: International 2 Insights from the TECOS Trial
Neha J. Pagidipati, Ann Marie Navar, Karen S. Pieper, Jennifer B. Green, M. Angelyn Bethel, Paul W. Armstrong, Robert G. Josse, Darren K. McGuire, Yuliya Lokhnygina, Jan H. Cornel, Sigrun Halvorsen, Timo E. Strandberg, Tuncay Delibasi, Rury R. Holman, Eric D. Peterson, On behalf of the TECOS Study Group
Circulation 2017;136:1193–1203. Published:26-Sep-2017. Epub:16-Jun-2017. PMID:28626088. doi:10.1161/CIRCULATIONAHA.117.027252

Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Robert J. Mentz , M. Angelyn Bethel, Stephanie Gustavson, Vivian P. Thompson, Neha J. Pagidipati, John B. Buse, Juliana C. Chan, Nayyar Iqbal, Aldo P. Maggioni, Steve P. Marso, Peter Ohman, Neil Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F. Hernandez, Rury R. Holman
Am Heart J. 2017;187:1-9. Published:14-Sep-2017. Epub:12-Feb-2017. PMID:28454792. doi:10.1016/j.ahj.2017.02.005

Do Glycoalbumin Levels Preferentially Reflect Changes in Postprandial Glucose Excursions?
S. K. Paul and R. R. Holman
Diab Med. 2017;34:1284–1290. Published:Sep-2017. Epub:13-Jun-2017. PMID:28477414. doi:10.1111/dme.13376

Continuous Glucose Monitoring Detected Hypoglycaemia in the Treating to Target in Type 2 Diabetes Trial (4-T)
JC Levy, MJ Davies, RR Holman, for the 4-T Study Group
Diabetes Res Clin Pract. 2017;131:161–168. Published:Sep-2017. Epub:21-Mar-2017. PMID:28750219. doi:10.1016/j.diabres.2017.01.022

Metformin – 60 years of clinical experience
Ed. Ian W Campbell, Harry CS Howlett, Rury R Holman, Clifford J Bailey
ISBN 978-3-527-34449-9 2017;1-122. Published:Sep-2017

Microvascular outcomes in type 2 diabetes - Authors' reply
Sophia Zoungas, Hertzel C Gerstein, Rury R Holman, Peter Reaven, Mark Woodward, Hisatomi Arima, Ruth L Coleman, John Chalmers, the Collaborators on Trials of Lowering Glucose (CONTROL) writing group
Lancet Diabetes Endocrinol 2017;5:580. Published:Aug-2017. PMID:28732664. doi:10.1016/S2213-8587(17)30185-7

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, Hayward RA, Craven T, Coleman RL, Chalmers J; Collaborators on Trials of Lowering Glucose (CONTROL) group
Lancet Diabetes Endocrinol. 2017;5:431-437. Published:Jun-2017. Epub:29-Mar-2017. PMID:28365411. doi:10.1016/S2213-8587(17)30104-3

Corrections needed to 2016 ESC and AHA guidelines on heart failure
Lars Rydén, Frans Van de Werf, Paul W Armstrong, Darren K McGuire, Eberhard Standl, Eric D Peterson, Rury R Holman
Lancet Diabetes Endocrinol. 2017;5:325-326. Published:May-2017. Epub:05-Apr-2017. PMID:28395875. doi:10.1016/S2213-8587(17)30102-X

Updated risk factors should be used to predict development of diabetes
Mary Angelyn Bethel, Kristen A. Hyland, Antonio R. Chacra, Prakash Deedwania, Gregory R. Fulcher, Rury R. Holman, Trond Jenssen, Naomi S. Levitt, John J.V. McMurray, Eleni Boutati, Laine Thomas, Jie-Lena Sun, Steven M. Haffner for the NAVIGATOR Study Group
J Diabetes Complications 2017;31:859-863. Published:May-2017. Epub:02-Mar-2017. PMID:28319004. doi:10.1016/j.jdiacomp.2017.02.012

Effect of gonadotropin inhibitory hormone (GnIH) on luteinizing hormone secretion in humans
George JT, Hendrikse M, Veldhuis JD, Clarke IJ, Anderson RA, Millar RP
Clin Endocrinol (Oxf). 2017;86:731-738. Published:May-2017. Epub:10-Feb-2017. PMID:28186349. doi:10.1111/cen.13308

Letter regarding AHA Scientific Statement “Drugs That May Cause or Exacerbate Heart Failure.”
Peterson ED, Armstrong PW, Holman RR
AHA website 2017;1. Published:Apr-2017. Epub:27-Apr-2017
[Full text]

Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS)
M. Angelyn Bethel, Samuel S. Engel, Jennifer B. Green, Zhen Huang, Robert G. Josse, Keith D. Kaufman, Eberhard Standl, Shailaja Suryawanshi, Frans Van de Werf, Darren K. McGuire, Eric D. Peterson, Rury R. Holman, for the TECOS Study Group
Diabetes Care 2017;40:494–501. Published:Apr-2017. Epub:05-Jan-2017. PMID:28057693. doi:10.2337/dc16-1135

Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial
Sharma A, de Souza Brito F2, Sun JL, Thomas L, Haffner S, Holman RR, Lopes RD
Am Heart J. 2017;186:73-82. Published:Apr-2017. Epub:29-Dec-2016. PMID:28454835. doi:10.1016/j.ahj.2016.12.011

Sustained influence of metformin therapy on circulating GLP-1 levels in individuals with and without type 2 diabetes
Preiss D, Dawed A, Welsh P, Heggie A, Jones AG, Dekker J, Koivula R, Hansen TH; DIRECT consortium, Stewart MC, Holman RR, Franks PW, Walker M, Pearson ER, Sattar N
Diabetes Obes Metab. 2017;19:356–363. Published:Mar-2017. Epub:13-Nov-2016. PMID:278628. doi:10.1111/dom.12826

Modeling the oral glucose tolerance test in normal and impaired glucose tolerant states: a population approach
Theodorakis MJ, Katsiki N, Arampatzi K, Chrousos GP
Curr Med Res Opin. 2017;33:305-313. Published:Feb-2017. Epub:31-Dec-2016. PMID:27794624. doi:10.1080/03007995.2016.1254607

Pancreatic Safety of Sitagliptin in the TECOS Study.
Buse JB, Bethel MA, Green JB, Stevens SR, Lokhnygina Y, Aschner P, Grado CR, Tankova T, Wainstein J, Josse R, Lachin JM, Engel SS, Patel K, Peterson ED, Holman RR; TECOS Study Group.
Diabetes Care 2017;40:164-170. Published:Feb-2017. Epub:14-Sep-2016. PMID:27630212. doi:10.2337/dc15-2780

International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance
Harumi Higuchi Dos Santos M, Sharma A, Sun JL, Pieper K, McMurray JJ, Holman RR, Lopes RD
J Am Heart Assoc 2017;6:e003892. Published:13-Jan-2017. Epub:13-Jan-2017. PMID:28087508. doi:10.1161/JAHA.116.003892

Sitagliptin and Risk of Fractures in Type 2 Diabetes: Results from the TECOS Trial
Josse RG, Majumdar SR, Zheng Y, Adler A, Bethel MA, Buse JB, Green JB, Kaufman KD, Rodbard HW, Tankova T, Westerhout CM, Peterson ED, Holman RR, Armstrong PW; TECOS Study Group
Diabetes Obes Metab 2017;19:78-86.. Published:Jan-2017. Epub:08-Sep-2016. PMID:27607571. doi:10.1111/dom.12786

Effect of valsartan on kidney outcomes in people with impaired glucose tolerance
Currie G, Angelyn Bethel M, Holzhauer B, Haffner SM, Holman RR, McMurray JJ
Diabetes Obes Metab. 2017;19:791-799. Epub:17-Jul-2017. PMID:28093841. doi:10.1111/dom.12877

Sodium-glucose cotransporter 2 inhibitors (SGLT2i): their role in cardiometabolic risk management
Katsiki N, Mikhailidis DP, Theodorakis MJ
Curr Pharm Des. 2017;23:1522-1532. Epub:13-Jan-2017. PMID:28088910. doi:10.2174/1381612823666170113152742

Evaluation of the Efficacy, Safety, and Glycaemic Effects of Evolocumab (AMG 145) in Hypercholesterolaemic Patients Stratified by Glycaemic Status and Metabolic Syndrome.
Blom DJ, Koren MJ, Roth E, Monsalvo ML, Djedjos CS, Nelson P, Elliott M, Wasserman SM, Ballantyne CM, Holman RR.
Diabetes, Obesity and Metabolism 2016;19:98-107. Published:Jan-2017. Epub:13-Sep-2016. PMID:27619750. doi:10.1111/dom.12788

Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
Jan H. Cornel, George L. Bakris, Susanna R. Stevens, Michael Alvarsson, Willem A. Bax, Lee-Ming Chuang, Samuel S. Engel, Renato D. Lopes, Darren K. McGuire, Axel Riefflin, Helena Wachslicht Rodbard, Isaac Sinay, Tsvetalina Tankova, Julio Wainstein, Eric D. Peterson, and Rury R. Holman, on behalf of the TECOS Study Group
Diabetes Care 2016;39:2304-2310. Published:Dec-2016. Epub:14-Oct-2016. PMID:27742728. doi:10.2337/dc16-1415

Neurokinin B Receptor Antagonism in Women with Polycystic Ovary Syndrome: A Randomized, Placebo- Controlled Trial
Jyothis T George, Rahul Kakkar, Jayne Marshall, Martin L Scott, Richard D Finkelman, Tony W Ho, Johannes Veldhuis, Karolina Skorupskaite, Richard A Anderson, Stuart McIntosh, Lorraine Webber
J Clin Endocrinol Metab 2016;101:4313-4321. Published:Nov-2016. Epub:26-Jul-2016. PMID:27459523. doi:10.1210/jc.2016-1202

Effect of metformin therapy on circulating amino acids in a randomized trial: the CAMERA study: Metabolism
D. Preiss, N. Rankin, P. Welsh, R. R. Holman, A. J. Kangas, P. Soininen, P. Würtz, M. Ala-Korpela and N. Sattar
Diab Med. 2016;33:1569-1574. Published:Nov-2016. Epub:16-Feb-2016. PMID:26887663. doi:10.1111/dme.13097

The effect of a brief action planning intervention on adherence to double-blind study medication, compared to a standard trial protocol, in the Atorvastatin in Factorial with Omega EE90 Risk Reduction in Diabetes (AFORRD) clinical trial: a cluster randomised sub-study
Andrew J. Farmer, Jason Oke, Wendy Hardeman, Lynne Tucker, Stephen Sutton, Ann-Louise Kinmonth, Simon Griffin, Rury R. Holman
Diabetes Res Clin Pract. 2016;120:56-64. Published:Oct-2016. Epub:30-Jul-2016. PMID:27522034. doi:10.1016/j.diabres.2016.07.004

Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin
Kaixin Zhou, Sook Wah Yee, Eric L Seiser, Nienke van Leeuwen, Roger Tavendale, Amanda J Bennett, Christopher J Groves, Ruth L Coleman, Amber A van der Heijden, Joline W Beulens, Catherine E de Keyser, Linda Zaharenko, Daniel M Rotroff, Mattijs Out, Kathleen A Jablonski, Ling Chen, Martin Javorský, Jozef Židzik, Albert M Levin, L Keoki Williams, Tanja Dujic, Sabina Semiz, Michiaki Kubo, Huan-Chieh Chien, Shiro Maeda, John S Witte, Longyang Wu, Ivan Tká?, Adriaan Kooy, Ron H N van Schaik, Coen D A Stehouwer, Lisa Logie, MetGen Investigators, DPP Investigators, ACCORD Investigators, Calum Sutherland, Janis Klovins, Valdis Pirags, Albert Hofman, Bruno H Stricker, Alison A Motsinger-Reif, Michael J Wagner, Federico Innocenti, Leen M ’t Hart, Rury R Holman, Mark I McCarthy, Monique M Hedderson, Colin N A Palmer, Jose C Florez, Kathleen M Giacomini & Ewan R Pearson
Nature Genetics 2016;48:1055-9. Published:Sep-2016. Epub:08-Aug-2016. PMID:27500523. doi:10.1038/ng.3632

Toward Fairness in Data Sharing
The International Consortium of Investigators for Fairness in Trial Data Sharing
N Engl J Med 2016;375:405-407. Published:04-Aug-2016. PMID:27518658. doi:10.1056/NEJMp1605654

Preface – Diabetes prevention and management
Rury R. Holman
Best Pract Res Clin Endocrinol Metab. 2016;30:329. Published:Jun-2016. Epub:16-Jul-2016. PMID:27432068. doi:10.1016/j.beem.2016.07.001

This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes
Gwilt M, Ryder REJ, Holman RR
British Journal of Diabetes 2016;16:88-92. Published:Jun-2016. doi:10.15277/bjd.2016.082

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus
Darren K. McGuire, Frans Van deWerf, PaulW. Armstrong, Eberhard Standl, Joerg Koglin, Jennifer B. Green, M. Angelyn Bethel, Jan H. Cornel, Renato D. Lopes, Sigrun Halvorsen, Giuseppe Ambrosio, John B. Buse, Robert G. Josse, John M. Lachin, Michael J. Pencina, Jyotsna Garg, Yuliya Lokhnygina, Rury R. Holman, Eric D. Peterson, for the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group
JAMA Cardiology 2016;1:126-135. Published:May-2016. Epub:13-Apr-2016. PMID:27437883. doi:10.1001/jamacardio.2016.0103

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial [Chinese republication]
Rury R Holman, Mary A Bethel, Juliana CN Chan, Jean-Louis Chiasson, Zoë Doran, Junbo Ge, Hertzel Gerstein, Yong Huo, John J McMurray, Lars Ryden, Winitha Liyanage, Stefan Schröder, Michal Tendera, Michael J Theodorakis, Jaakko Tuomilehto, Wenying Yang, Dayi Hu, Changyu Pan for the ACE Study Group
Int J Endocrinol Metab 2016;36:1-4. Published:May-2016. doi:10.3760/cma.j.issn.1673-4157.201.00.00

Rationale and Design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) Trial
Rury R. Holman, M. Angelyn Bethel, Jyothis George, Harald Sourij, Zoë Doran, Joanne Keenan, Nardev S. Khurmi, Robert J. Mentz, Abderrahim Oulhaj, John B. Buse, Juliana C. Chan, Nayyar Iqbal, Sudeep Kundu, Aldo P. Maggioni, Steven P. Marso, Peter Öhman, Michael J. Pencina, Neil Poulter, Lisa E. Porter, Ambady Ramachandran, Bernard Zinman, Adrian F.Hernande
American Heart Journal 2016;174:103-110. Published:Apr-2016. Epub:21-Dec-2015. PMID:26995376. doi:10.1016/j.ahj.2015.12.009

Adherence to Oral Glucose-Lowering Therapies and Associations With 1-year HbA1c: A Retrospective Cohort Analysis in a Large Primary Care Database
Andrew J. Farmer, Lauren R Rodgers, Mike Lonergan, Beverley Shields, Michael Weedon, Louise Donnelly, Rury R. Holman, Ewan R. Pearson, Andrew T Hattersley for the MASTERMIND consortium
Diabetes Care 2016;39:258-263. Published:Feb-2016. Epub:17-Dec-2015. PMID:26681714. doi:10.2337/dc15-1194

Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes
M.A. Bethel, P Harrison, H Sourij, Y Sun, L Tucker, I Kennedy , S White, L Hill, A Oulhaj, R Coleman, R.R. Holman
Diab Med. 2016;33:224-230. Published:Feb-2016. Epub:14-Jul-2015. PMID:26043186. doi:10.1111/dme.12828

On the potential of acarbose to reduce cardiovascular disease [Chinese republication]
Standl E, Theodorakis MJ, Erbach M, Schnell O, Tuomilehto J, Pan CY
Int J Endocrinol Metab 2016;36:3-4. Published:Jan-2016. doi:10.3760/cma.j.issn.1673-4157.2016.01.001

Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes - Authors' reply
Rury R. Holman, Eric D. Peterson
N Eng J Med 2015;373:2479. Published:17-Dec-2015. PMID:26672857. doi:10.1056/NEJMc1510995

Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study
David Preiss, Laine E Thomas, Daniel M Wojdyla, Steven M Haffner, Jason M R Gill, Thomas Yates, Melanie J Davies, Rury R Holman, John J McMurray, Robert M Califf, William E Kraus, on behalf of the NAVIGATOR investigators
BMJ Open 2015;5:e007901. Published:11-Nov-2015. Epub:14-Aug-2015. PMID:26275900. doi:10.1136/bmjopen-2015-007901

Cardiovascular outcome trials of glucose-lowering drugs in type 2 diabetes: 10 frequently asked questions
Jyothis George
Practical Diabetes 2015;32:301-304. Published:Oct-2015. Epub:16-Oct-2015. doi:10.1002/pdi.1976

GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study.
Michael J. Theodorakis
Diabetes 2015;64:e28-e29. Published:Sep-2015. Epub:01-Sep-2015. PMID:26294437. doi:10.2337/db15-0614

Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial
T. Yates, M. J. Davies, S. M. Haffner, P. J. Schulte, L. Thomas, K. M. Huffman, C. W. Bales, D. Preiss, R. M. Califf, R. R. Holman, J. J. V. McMurray, M. A. Bethel, J. Tuomilehto and W. E. Kraus
Diab Med. 2015;32:1090-1096. Published:Aug-2015. Epub:12-Apr-2015. PMID:25818859. doi:10.1111/dme.12762

Physiology of GNRH and Gonadotropin Secretion
Pedro Marques, Karolina Skorupskaite, Kavitha S. Rozario, Richard A. Anderson and Jyothis T. George
Endotext 2015;1:1-30. Published:31-Jul-2015. PMID:25905297

Insulin dose adjustments with add-on glucagon-like peptide-1 receptor (GLP-1R) agonists in clinical practice
Carla Francés Artigas, Victoria Stokes, Garry D Tan and Michael J Theodorakis
Expert Opin. Pharmacother. 2015;16:1417-1421. Published:17-Jul-2015. Epub:16-Jun-2015. PMID:26077113. doi:10.1517/14656566.2015.1052740

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green, M. Angelyn Bethel, Paul W. Armstrong, John B. Buse, Samuel S. Engel, Jyotsna Garg, Robert Josse, Keith D. Kaufman, Joerg Koglin, Scott Korn, John M. Lachin, Darren K. McGuire, Michael J. Pencina, Eberhard Standl, Peter P. Stein, Shailaja Suryawanshi, Frans Van de Werf, Eric D. Peterson, and Rury R. Holman, on behalf of the TECOS Study Group
N Engl J Med 2015;373:232-242. Published:16-Jul-2015. Epub:08-Jun-2015. PMID:26052984. doi:10.1056/NEJMoa1501352
Erratum in :
N Engl J Med 201;373:586, Print:06-Aug-2015, Epub:16-Jul-2015, PMID:26182233, doi:10.1056/NEJMx150029

The University of Oxford Diabetes Trials Unit
Mark Nicholls, Rury Holman
European Heart Journal 2015;36:1706-07. Published:14-Jul-2015. PMID:26393241

Within-class differences of the sulfonylureas should be accounted for. Reply to Schrijnders D, Kleefstra N and Landman GWD
Jonathan C. Levy, Axel Riefflin & Rury R. Holman
Diabetologia 2015;58:1376-7. Published:Jun-2015. Epub:26-Mar-2015. PMID:25810041. doi:10.1007/s00125-015-3574-z

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial [Chinese Abstract]
Hu Da Yi, Pan Chang Yu, Rury R. Holman.
Chinese Journal of Cardiology 2015;43:412. Published:24-May-2015. doi:10.3760/cma.j.issn.0253-3758.2015.05.008

How does obesity affect fertility in men - and what are the treatment options?
Victoria J. Stokes, Richard A. Anderson and Jyothis T. George
Clinical Endocrinology 2015;82:633-8. Published:May-2015. Epub:16-Sep-2014. PMID:25138694. doi:10.1111/cen.12591

Normal weight individuals with type 2 diabetes: The Personal Fat Threshold
Roy Taylor and Rury R. Holman
Clin Sci (Lond). 2015;128:405-410. Published:01-Apr-2015. PMID:25515001. doi:10.1042/CS20140553

Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
M. A. Bethel, J. B. Green, J.Milton, A.Tajar, S.S.Engel, R.M.Califf, R.R.Holman on behalf of the TECOS Executive Committee
Diabetes, Obesity and Metabolism 2015;17:395-402. Published:Apr-2015. Epub:13-Feb-2015. PMID:25600421. doi:10.1111/dom.12441

The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84)
M. L. Alva, A. Gray, B. Mihaylova, J. Leal and R. R. Holman
Diab Med. 2015;32:459-466. Published:Apr-2015. Epub:07-Jan-2015. PMID:25439048. doi:10.1111/dme.12647

Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials
The Blood Pressure Lowering Treatment Trialists’ Collaboration
Lancet 2015;385:867-74. Published:07-Mar-2015. Epub:04-Nov-2014. PMID:25468168. doi:10.1016/S0140-6736(14)61171-5

Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus
M. A. Bethel, W. Xu, M. J. Theodorakis
Diabetes, Obesity and Metabolism 2015;17:231-244. Published:Mar-2015. Epub:27-Nov-2014. PMID:25312701. doi:10.1111/dom.12401

The effect of glibenclamide on insulin secretion at normal glucose concentrations
Axel Riefflin, Usha Ayyagari, Susan E. Manley, Rury R. Holman, Jonathan C. Levy
Diabetologia 2015;58:43-49. Published:Jan-2015. Epub:09-Oct-2014. PMID:25297572. doi:10.1007/s00125-014-3399-1

Chronic Obstructive Pulmonary Disease and Cardiovascular Risk: Insights from the NAVIGATOR Trial
Pedro G.M. de Barros e Silva, Robert M. Califf, Jie-Lena Sun, John J.V. McMurray, Rury R. Holman, Steven Haffner, Laine Thomas, Renato D. Lopes
International Joural of Cardiology 2014;176:1126-1128. Published:25-Mar-2015. Epub:12-Aug-2014. PMID:25220176. doi:10.1016/j.ijcard.2014.07.297

Performance of the UKPDS Outcomes Model for Prediction of Myocardial Infarction and Stroke in the ADDITION-Europe Trial Cohort: does the ADDITION validation add up? – Authors' reply
Alastair Gray, Rury Holman, Philip Clarke, Jose Leal
Value in Health 2014;17:895-6. Published:Dec-2014. Epub:22-Sep-2014. PMID:25498785. doi:10.1016/j.jval.2014.07.008

Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study
D. Preiss, S. M. Haffner, L. E.Thomas, J.-L. Sun, N. Sattar, T. Yates, M. J Davies, J. J. McMurray, R. R. Holman, R. M. Califf & W. E. Kraus
Diabetes Obesity and Metabolism 2014;16:1265-1268. Published:Dec-2014. Epub:19-Jun-2014. PMID:24861892. doi:10.1111/dom.12320

Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
John J V McMurray, Hertzel C Gerstein, Rury R Holman, Marc A Pfeffer
Lancet Diabetes Endocrinol. 2014;2:843-851. Published:Oct-2014. Epub:13-Mar-2014. PMID:24731668. doi:10.1016/S2213-8587(14)70031-2

Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes. Authors' reply
Rury R. Holman, Harald Sourij, Robert M. Califf
The Lancet 2014;384:1097-1098. Published:20-Sep-2014. PMID:25241719. doi:10.1016/S0140-6736(14)61674-3

Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data
The Blood Pressure Lowering Treatment Trialists' Collaboration
The Lancet 2014;384:591-598. Published:16-Aug-2014. Epub:14-Aug-2014. PMID:25131978. doi:10.1016/S0140-6736(14)61212-5

Cardiovascular endocrinology: First-time heart failure increases risk of diabetes mellitus
Rury R. Holman
Nat. Rev. Endocrinol. 2014;10:453-454. Published:Aug-2014. Epub:01-Jul-2014. PMID:24981458. doi:10.1038/nrendo.2014.105

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial
Rury R Holman, Mary A Bethel, Juliana CN Chan, Jean-Louis Chiasson, Zoë Doran, Junbo Ge, Hertzel Gerstein, Yong Huo, John J McMurray, Lars Ryden, Winitha Liyanage, Stefan Schröder, Michal Tendera, Michael J Theodorakis, Jaakko Tuomilehto, Wenying Yang, Dayi Hu, Changyu Pan for the ACE Study Group
American Heart Journal 2014;168:23-29. Published:Jul-2014. Epub:05-Apr-2014. PMID:24952856. doi:10.1016/j.ahj.2014.03.021

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
Rury R Holman, Harald Sourij, Robert M Califf
Lancet 2014;383:2008-17. Published:07-Jun-2014. Epub:05-Jun-2014. PMID:24910232. doi:10.1016/S0140-6736(14)60794-7

On the potential of acarbose to reduce cardiovascular disease
Eberhard Standl, Michael J Theodorakis, Michael Erbach, Oliver Schnell and Jaakko Tuomilehto
Cardiovascular Diabetology 2014;13:81. Published:16-Apr-2014. PMID:24742256. doi:10.1186/1475-2840-13-81

Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: Results from NAVIGATOR
Huffman KM, Sun JL, Thomas L, Bales CW, Califf RM, Yates T, Davies MJ, Holman RR, McMurray JJ, Bethel MA, Tuomilehto J, Haffner SM, Kraus WE.
Metabolism 2014;63:554-561. Published:Apr-2014. Epub:15-Jan-2014. PMID:24559843. doi:10.1016/j.metabol.2014.01.002

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis
Thomas Yates, Steven M Haffner, Phillip J Schulte, Laine Thomas, Kim M Huff man, Connie W Bales, Robert M Califf , Rury R Holman, John J V McMurray, M Angelyn Bethel, Jaakko Tuomilehto, Melanie J Davies, William E Kraus
Lancet 2014;383:1059-66. Published:22-Mar-2014. Epub:20-Dec-2013. PMID:24361242. doi:10.1016/S0140-6736(13)62061-9

Ethnicity and long-term vascular outcomes in Type 2 diabetes: a prospective observational study (UKPDS 83)
T. M. E. Davis, R. L. Coleman and R. R. Holman for the UKPDS Group
Diab Med. 2014;31:200-207. Published:Feb-2014. Epub:22-Nov-2013. PMID:24267048. doi:10.1111/dme.12353

Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial
David Preiss, Suzanne M Lloyd, Ian Ford, John J McMurray, Rury R Holman, Paul Welsh, Miles Fisher, Chris J Packard, Naveed Sattar
Lancet Diabetes & Endocrinology 2014;2:116-124. Published:Feb-2014. Epub:07-Nov-2013. PMID:24622715. doi:10.1016/S2213-8587(13)70152-9

Role of diuretics, beta blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study
Lan Shen, Bimal R Shah, Eric M Reyes, Laine Thomas, Daniel Wojdyla, Peter Diem, Lawrence A Leiter, Bernard Charbonnel, Viacheslav Mareev, Edward S Horton, Steven M Haffner, Vladimir Soska, Rury Holman, M Angelyn Bethel, Frank Schaper, Jie-Lena Sun, John JV McMurray, Robert M Califf, Henry Krum
British Medical Journal 2013;347:f6745. Published:09-Dec-2013. PMID:24322398. doi:10.1136/bmj.f6745

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
Jennifer B. Green, M. Angelyn Bethel, Sanjoy K. Paul, Arne Ring, Keith D. Kaufman, Deborah R. Shapiro, Robert M. Califf, Rury R. Holman
American Heart Journal 2013;166:983-989.e7. Published:Dec-2013. Epub:23-Oct-2013. PMID:24268212. doi:10.1016/j.ahj.2013.09.003

UKPDS - The first 30 years (Chinese version)
Holman RR, Watkins PJ
2013; . Published:18-Nov-2013

Incidence of atrial fibrillation in a population with impaired glucose tolerance: The contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial
Latini R, Staszewsky L, Sun JL, Bethel MA, Disertori M, Haffner SM, Holman RR, Chang F, Giles TD, Maggioni AP, Rutten GE, Standl E, Thomas L, Tognoni G, Califf RM, McMurray JJ
American Heart Journal 2013;166:935-940.e1. Published:Nov-2013. Epub:07-Oct-2013. PMID:24176451. doi:10.1016/j.ahj.2013.08.012

Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial
David Preiss, Thomas D. Giles, Laine E. Thomas, Jie-Lena Sun, Steven M. Haffner, Rury R. Holman, Eberhard Standl, Theodore Mazzone, Guy E. Rutten, Gianni Tognoni, Fu-Tien Chiang, John J.V. McMurray, Robert M. Califf
Stroke 2013;44:2590-2593. Published:Sep-2013. Epub:30-Jul-2013. PMID:23899915. doi:10.1161/STROKEAHA.113.001177

UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82
Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM
Diabetologia 2013;56:1925-1933. Published:Sep-2013. Epub:22-Jun-2013. PMID:23793713. doi:10.1007/s00125-013-2940-y

A Novel Risk Classification Paradigm for Patients With Impaired Glucose Tolerance and High Cardiovascular Risk
Bethel MA, Chacra AR, Deedwania P, Fulcher GR, Holman RR, Jenssen T, Kahn SE, Levitt NS, McMurray JJ, Califf RM, Raptis SA, Thomas L, Sun JL, Haffner SM
Am J Cardiol 2013;112:231-237. Published:15-Jul-2013. Epub:19-Apr-2013. PMID:23608615. doi:10.1016/j.amjcard.2013.03.019

Evaluation of a Self-Administered Oral Glucose Tolerance Test
M. Angelyn Bethel, Hermione C. Price, Harald Sourij, Sarah White, Ruth L. Coleman, Arne Ring, Irene E. C. Kennedy, Lynne Tucker, and Rury R. Holman
Diabetes Care 2013;36:1483-1488. Published:Jun-2013. Epub:15-Jan-2013. PMID:23321216. doi:10.2337/dc12-0643

Temporal Validation of the UKPDS Outcomes Model Using 10-Year Post trial Monitoring Data
Leal J, Hayes AJ, Gray AM, Holman RR, Clarke PM.
Diabetes Care 2013;36:1541-1546. Published:Jun-2013. Epub:28-Dec-2012. PMID:23275370. doi:10.2337/dc12-1120

Metformin and mortality. Reply to Lund SS
R. J. Stevens, B. J. Cairns , R. R. Holman
Diabetologia 2013;56:939-940. Published:Apr-2013. Epub:09-Feb-2013. PMID:23397291. doi:10.1007/s00125-013-2844-x

Prognostic Significance of Silent Myocardial Infarction in Newly-Diagnosed Type 2 Diabetes: UKPDS 79
Timothy M.E. Davis; Ruth L. Coleman; Rury R. Holman
Circulation 2013;127:980-987. Published:05-Mar-2013. Epub:29-Jan-2013. PMID:23362315. doi:10.1161/CIRCULATIONAHA.112.000908

Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive
Holman RR
Nature Reviews Endocrinology 2013;9:67-68. Published:Feb-2013. Epub:08-Jan-2013. PMID:23296166. doi:10.1038/nrendo.2012.243

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
David Preiss, Laine E Thomas, Jie-Lena Sun, Steven M Haffner, Rury R Holman, Eberhard Standl, Lawrence A Leiter, Theodore Mazzone, Guy E Rutten, Gianni Tognoni, Felipe A Martinez, Fu-Tien Chiang, Robert M Califf, John J McMurray
BMJ Open 2012;2:e001925. Published:30-Nov-2012. Epub:30-Nov-2012. PMID:23204139. doi:10.1136/bmjopen-2012-001925

Editorial: Warning signals from clinical trials: all that glitters is not gold (Chinese translation)
Rury R Holman
Chinese Journal of Diabetes Mellitus 2012;4:513-516. Published:17-Oct-2012

Prediabetes and the risk of diabetes – Authors' reply
John JV McMurray, Steven M Haffner, Robert M Califf, Rury R Holman
The Lancet 2012;380:1225-1226. Published:06-Oct-2012. PMID:23040850. doi:10.1016/S0140-6736(12)61706-1

Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials
R.J. Stevens, R.Ali, C.R. Bankhead, M.A. Bethel, B.J. Cairns, R.P. Camisasca, F.L. Crowe, A.J. Farmer, S. Harrison, J.A. Hirst, P. Home, S.E. Kahn, J.H. McLellan, R. Perera, A. Plüddemann, A. Ramachandran, N.W. Roberts, P.W. Rose, A. Schweizer, G. Viberti, R. R. Holman
Diabetologia 2012;55:2593-2603. Published:Oct-2012. Epub:10-Aug-2012. PMID:22875195. doi:10.1007/s00125-012-2653-7

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Hypertension on Clinical End Points: A Cohort Study
John J.V. McMurray, Robert M. Califf, Angelyn M. Bethel, Steven M. Haffner, Rury R. Holman
The Journal of Clinical Hypertension 2012;14:731. Published:Oct-2012. Epub:26-Jul-2012. PMID:23031154. doi:10.1111/j.1751-7176.2012.00687.x

Disseminating results to clinical trial participants: a qualitative review of patient understanding in a post-trial population
Julie Lorraine Darbyshire, Hermione Clare Price
BMJ Open 2012;2:e001252. Published:24-Sep-2012. PMID:23012330. doi:10.1136/bmjopen-2012-001252

A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts
van Leeuwen N, Nijpels G, Becker ML, Deshmukh H, Zhou K, Stricker BH, Uitterlinden AG, Hofman A, van 't Riet E, Palmer CN, Guigas B, Slagboom PE, Durrington P, Calle RA, Neil A, Hitman G, Livingstone SJ, Colhoun H, Holman RR, McCarthy MI, Dekker JM, 't Hart LM, Pearson ER.
Diabetologia 2012;55:1971-7. Published:Jul-2012. Epub:28-Mar-2012. PMID:22453232. doi:10.1007/s00125-012-2537-x

Addition of exenatide to insulin therapy in individuals with type 2 diabetes in UK routine clinical practice
Hermione C Price, Catherine Gorst, Usha Ayyagari, Jonathan Levy and Rury R Holman
Practical Diabetes 2012;29:61-64. Published:Mar-2012. Epub:06-Mar-2012. doi:10.1002/pdi.1660

Letter in response to Wannamethee et al: Women develop diabetes at higher BMIs than men
H. Sourij, R. R. Holman
Diabetologia 2012;55:855-6. Published:Mar-2012. Epub:06-Jan-2012. PMID:22222506. doi:10.1007/s00125-011-2437-5

Understanding the outcomes of multi-centre clinical trials: a qualitative study of health professional experiences and views
Lawton J, Jenkins N, Darbyshire J, Farmer A, Holman R, Hallowell N
Social Science & Medicine 2012;74:574-81. Published:Feb-2012. Epub:23-Dec-2011. PMID:22236642. doi:10.1016/j.socscimed.2011.11.012

Impact of FDA Guidance for Developing Diabetes Drugs on Trial Design: From Policy to Practice
M. Angelyn Bethel & Harald Sourij
Current Cardiology Reports 2012;14:59-69. Published:Feb-2012. Epub:18-Nov-2011. PMID:22094711. doi:10.1007/s11886-011-0229-7

Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial
Punthakee Z, Bosch J, Dagenais G, Diaz R, Holman R, Probstfield JL, Ramachandran A, Riddle MC, Rydén LE, Zinman B, Afzal R, Yusuf S, Gerstein HC; TIDE Trial Investigators.
Diabetologia 2012;55:36-45. Published:Jan-2012. Epub:29-Oct-2011. PMID:22038523. doi:10.1007/s00125-011-2357-4

All That Glitters Is Not Gold: Why we need better trials and reporting
Rury R Holman
Diabetes Voice 2011;56:32. Published:Dec-2011. PMID:21767341. doi:10.1111/j.1463-1326.2011.01475.x

Differences in insulin treatment satisfaction following randomized addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes
Farmer AJ, Oke J, Stevens R, Holman RR
Diabetes, Obesity and Metabolism 2011;13:1136-1141. Published:16-Nov-2011. PMID:21767341. doi:10.1111/j.1463-1326.2011.01475.x

Incidence of Diabetes Following Ramipril and Rosiglitazone Withdrawal
Rury R Holman FRCP, B Zinman, S Yusaf, P Sheridan, S Anand, J Bosch, I Conget, M Davies, V Pirags, J Pogue, P Zimmet, HC Gerstein.
Diabetes Care 2011;34:1265-1269 . Published:Jun-2011. Epub:22-Apr-2011. PMID:21515846. doi:10.2337/dc10-1567

Challenges of maintaining research protocol fidelity in a clinical care setting: A qualitative study of the experiences and views of patients and staff participating in a randomized controlled trial
Julia Lawton, Nicholas Jenkins, Julie L Darbyshire, Rury R Holman, Andrew J Farmer and Nina Hallowell
Trials 2011;12: . Published:04-May-2011. PMID:21542916. doi:10.1186/1745-6215-12-108

Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy
John M. Lachin, Giancarlo Viberti, Bernard Zinman, Steven M. Haffner, R. Paul Aftring, Gitanjali Paul, Barbara G. Kravitz, William H. Herman, Rury R. Holman, Steven E. Kahn; ADOPT Study Group
Clin J Am Soc Nephrol 2011;6:1032-40. Published:May-2011. Epub:31-Mar-2011. PMID:21454723. doi:10.2215/CJN.09291010

Effects Of Rosiglitazone, Glyburide, and Metformin on beta-Cell Function and Insulin Sensitivity in ADOPT
Kahn SE, Lachin JM, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Viberti G, Holman RR; and the ADOPT Study Group
Diabetes 2011;60:1552-1560. Published:May-2011. Epub:17-Mar-2011. PMID:21415383. doi:10.2337/db10-1392

Participants' experiences of intensifying insulin therapy during the Treating to Target in Type 2 Diabetes (4-T) trial: qualitative interview study
N. Jenkins, N. Hallowell, A. J. Farmer, R. R. Holman, J. Lawton
Diab Med. 2011;28:543-548. Published:May-2011. PMID:21480965. doi:10.1111/j.1464-5491.2010.03200.x

Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals
The ARB Trialists Collaboration
Journal of Hypertension 2011;29:623-635. Published:Apr-2011. Epub:10-Feb-2011. PMID:21358417. doi:10.1097/HJH.0b013e328344a7de
Errata in :
Journal of Hypertension 2015;32:288, Print:Feb-2015, Epub:20-Jan-2015, doi:10.1111/dme.12672
Journal of Hypertension 2011;28:625, Print:May-2011, Epub:12-Apr-2011, doi:10.1111/j.1464-5491.2011.03267.x

Impact of personalised cardiovascular disease risk estimates on physical activity-a randomised controlled trial
Hermione C Price, Simon J Griffin, Rury R Holman
Diab Med. 2011;28:363-372. Published:Mar-2011. Epub:10-Feb-2011. PMID:21309847. doi:10.1111/j.1464-5491.2010.03212.x
Erratum in :
Diab Med. 2015;32:288, PMID:Feb-2015

Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes
The GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group & The Wellcome Trust Case Control Consortium
Nature Genetics 2010;43:117-120. Published:Feb-2011. Epub:26-Dec-2010. PMID:21186350. doi:10.1038/ng.735

Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: A randomised placebo controlled trial
H.A.W. Neil, U. Ceglarek, J. Thiery, S. Paul, A. Farmer, R. R Holman
Atherosclerosis 2010;213:512-517. Published:Dec-2010. Epub:18-Sep-2010. PMID:21036355. doi:10.1016/j.atherosclerosis.2010.09.013

Initiating insulin as part of the Treating to Target in Type 2 Diabetes (4-T) trial: A interview study of patients' and health care professionals' experiences
Nicholas Jenkins, Nina Hallowell, Andrew J. Farmer, Rury R. Holman, Julia Lawton
Diabetes Care 2010;33:2178-2180. Published:Oct-2010. Epub:30-Jun-2010. PMID:20592050. doi:10.2337/dc10-0494

Recommendations for Biomarker Identification and Qualification in Clinical Proteomics
Harald Mischak, Günter Allmaier, Rolf Apweiler, Teresa Attwood, Marc Baumann, Ariela Benigni, Samuel E. Bennett, Rainer Bischoff, Erik Bongcam-Rudloff, Giovambattista Capasso, Joshua J. Coon, Patrick D'Haese, Anna F. Dominiczak, Mohammed Dakna, Hassan Dihazi, Jochen H. Ehrich, Patricia Fernandez-Llama, Danilo Fliser, Jorgen Frokiaer, Jerome Garin, Mark Girolami, William S. Hancock, Marion Haubitz, Denis Hochstrasser, Rury R. Holman, John P. A. Loannidis, Joachim Jankowski, Bruce A. Julian, Jon B. Klein, Walter Kolch, Theo Luider, Ziad Massy, William B. Mattes, Franck Molina, Bernard Monsarrat, Jan Novak, Karlheinz Peter, Peter Rossing, Marta Sánchez-Carbayo, Joost P. Schanstra, O. John Semmes, Goce Spasovski, Dan Theodorescu, Visith Thongboonkerd, Raymond Vanholder, Timothy D. Veenstra, Eva Weissinger, Tadashi Yamamoto, Antonia Vlahou
Sci Transl Med. 2010;2:46ps42. Published:25-Aug-2010. PMID:20739680. doi:10.1126/scitranslmed.3001249

Effect of Valsartan on the Incidence of Diabetes - The authors reply.
Holman, R.R., Holzhauer, B., McMurray, J.J.
N Engl J Med. 2010;363:792-793. Published:19-Aug-2010. PMID:20718670. doi:10.1056/NEJMc1005899

Life Expectancy in Individuals with Type 2 Diabetes: Implications for Annuities
Hermione C. Price, Philip M. Clarke, Alastair M. Gray and Rury R. Holman
Medical Decision Making 2010;30:409-14. Published:20-May-2010. Epub:30-Dec-2009. PMID:20042534. doi:10.1177/0272989X09349960

Meta-analysis on insulin treatment for type 2 diabetes: rushed conclusions? Reply to Wägner AM, Mauricio D
A. J. Farmer & D. S. Lasserson & R. R. Holman
Diabetologia 2010;53:1004-5. Published:May-2010. Epub:23-Feb-2010. PMID:20157696. doi:10.1007/s00125-010-1679-y

Risk communication: Why, what and how?
Hermione C Price
Diabetes & Primary Care 2010;12:100-104. Published:May-2010
[Full text]

Baseline Characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial Population: Comparison with Other Diabetes Prevention Trials
Henry Krum, John J.V. McMurray, Edward Horton, Teresa Gerlock, Bjoern Holzhauer, Lineke Zuurman, Steven M. Haffner, M. Angelyn Bethel, Rury R. Holman, Robert M. Califf
Cardiovascular Therapeutics 2010;28(2):124-132. Published:29-Apr-2010. PMID:20184589. doi:10.1111/j.1755-5922.2010.00146.x

Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events
NAVIGATOR Study Group; Holman, R.R., Haffner, S.M., McMurray, J.J., Bethel, M.A., Holzhauer, B., Hua, T.A., Belenkov, Y., Boolell, M., Buse, J.B., Buckley, B.M., Chacra, A.R., Chiang, F.-T., Charbonnel, B., Chow, C.-C., Davies, M.J., Deedwania, P., Diem, P., Einhorn, D., Fonseca, V., Fulcher, G.R., Gaciong, Z., Gaztambide, S., Giles, T., Horton, E., Ilkova, H., Jenssen, T., Kahn, S.E., Krum, H., Laakso, M., Leiter, L.A., Levitt, N.S., Mareev, V., Martinez, F., Masson, C., Mazzone, T., Meaney, E., Nesto, R., Pan, C., Prager, R., Raptis, S.A., Rutten, G.E.H.M., Sandstroem, H., Schaper, F., Scheen, A., Schmitz, O., Sinay, I., Soska, V., Stender, S., Tamás, G., Tognoni, G., Tuomilehto, J., Villamil, A.S., Vozar, J., Califf, R.M.
N Engl J Med 2010;362:1463-76. Published:22-Apr-2010. Epub:14-Mar-2010. PMID:20228402. doi:10.1056/NEJMoa1001122
[Presentation] [Slides]

Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events
NAVIGATOR Study Group; John J McMurray, Rury R Holman, Steven M Haffner, M Angelyn Bethel, Björn Holzhauer, Tsushung A Hua, Yuri Belenkov, Mitradev Boolell, John B Buse, Brendan M Buckley, Antonio R Chacra, Fu-Tien Chiang, Bernard Charbonnel, Chun-Chung Chow, Melanie J Davies, Prakash Deedwania, Peter Diem, Daniel Einhorn, Vivian Fonseca, Gregory R Fulcher, Zbigniew Gaciong, Sonia Gaztambide, Thomas Giles, Edward Horton, Hasan Ilkova, Trond Jenssen, Steven E Kahn, Henry Krum, Markku Laakso, Lawrence A Leiter, Naomi S Levitt, Viacheslav Mareev, Felipe Martinez, Chantal Masson, Theodore Mazzone, Eduardo Meaney, Richard Nesto, Changyu Pan, Rudolf Prager, Sotirios A Raptis, Guy E H M Rutten, Herbert Sandstroem, Frank Schaper, Andre Scheen, Ole Schmitz, Isaac Sinay, Vladimir Soska, Steen Stender, Gyula Tamás, Gianni Tognoni, Jaako Tuomilehto, Alberto S Villamil, Juraj Vozár, Robert M Califf.
N Engl J Med 2010;362:1477-90. Published:22-Apr-2010. Epub:14-Mar-2010. PMID:20228403. doi:10.1056/NEJMoa1001121
[Presentation] [Slides]
Erratum in :
N Engl J Med 2010;362:1748, Print:06-May-2010

Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis
Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J, Gregg E, Holman RR, Kirkman MS, Stern M, Tuomilehto J, Wareham NJ
Lancet 2010;375:1365-1374. Published:17-Apr-2010. Epub:29-Mar-2010. PMID:20356621. doi:10.1016/S0140-6736(09)62162-0
Erratum in :
Lancet 2010;375:1346, Print:17-Apr-2010

Insulin Regimens in Type 2 Diabetes - Authors' reply
Rury R. Holman, Julie L. Darbyshire,
N Engl J Med 2010;362:960. Published:11-Mar-2010. PMID:20220196. doi:10.1056/NEJMc0911551

Evaluation of Serum 1,5 Anhydroglucitol Levels as a Clinical Test to Differentiate Subtypes of Diabetes
Aparna Pal, Christina Dudley, Mary Selwood, Beryl Barrow, Rhiannon Klyne, Jilly Grew, Andrew Farmer, Mark McCarthy, Anna Gloyn, Katharine Owen
Diabetes Care 2010;33:252-257. Published:Feb-2010. Epub:23-Nov-2009. PMID:19933992. doi:10.2337/dc09-1246

Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes
Bernard Zinman, Steven M. Haffner, William H. Herman, Rury R. Holman, John M. Lachin, Barbara G. Kravitz, Gitanjali Paul, Nigel P. Jones, R. Paul Aftring, Giancarlo Viberti, Steven E. Kahn, and the A Diabetes Outcome Progression Trial Study Group
J Clin Endocrinol Metab 2010;95:134-142. Published:Jan-2010. Epub:29-Oct-2009. PMID:19875477. doi:10.1210/jc.2009-0572

Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT)
Steven E. Kahn, Steven M. Haffner, Giancarlo Viberti, William H. Herman, John M. Lachin, Barbara G. Kravitz, Dahong Yu, Gitanjali Paul, Rury R. Holman, Bernard Zinman and for the ADOPT Study Group
Diabetes Care 2010;33:177-183. Published:Jan-2010. Epub:06-Oct-2009. PMID:19808911. doi:10.2337/dc09-1661
[Abstract]

Exenatide Case Report
Price HC, Holman RR
International Diabetes 2009;15:15. Published:24-Jan-2011
[Full text]

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
David M. Nathan, John B. Buse, Mayer B. Davidson, Ele Ferrannini, Rury R. Holman, Robert Sherwin, Bernard Zinman
Clinical Diabetes 2009;27:4-16. Published:21-Dec-2009. doi:10.2337/diaclin.27.1.4

Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population
M. A. Bethel, P. Deedwania, N. S. Levitt, O. Schmitz, A. Huntsman-Labed, R. M. Califf, S. M. Haffner and P. Diem for the NAVIGATOR Study Groupp
Diab Med. 2009;26:1204-1211. Published:Dec-2009. Epub:30-Sep-2009. PMID:20002471. doi:10.1111/j.1464-5491.2009.02864.x
[Abstract]

Perceptions of heart attack risk amongst individuals with diabetes
Hermione C Price, Christina Dudley, Beryl Barrow, Simon J Griffin & Rury R Holman
Primary Care Diabetes 2009;3:239 -244. Published:Nov-2009. Epub:05-Nov-2009. PMID:19896425. doi:10.1016/j.pcd.2009.09.005

Intensive glucose control and macrovascular outcomes in type 2 diabetes
Control Group; F M Turnbull, C Abraira, R J Anderson, R P Byington, J P Chalmers, W C Duckworth, G W Evans, H C Gerstein, R R Holman, T E Moritz, B C Neal, T Ninomiya, A A Patel, S K Paul, F Travert, M Woodward
Diabetologia 2009;52:2288-2298. Published:Nov-2009. Epub:05-Aug-2009. PMID:19655124. doi:10.1007/s00125-009-1470-0

Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
Rury R. Holman, Andrew J. Farmer, Melanie J. Davies, Jonathan C. Levy, Julie L. Darbyshire, Joanne F. Keenan, and Sanjoy K. Paul for the 4-T Study Group
N Eng J Med 2009;361:1736-47. Published:29-Oct-2009. Epub:22-Oct-2009. PMID:19850703. doi:10.1056/NEJMoa0905479
[Slides]

Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses
Lasserson DS, Glasziou P, Perera R, Holman RR, Farmer AJ
Diabetologia 2009;52:1990-2000. Published:Oct-2009. Epub:31-Jul-2009. PMID:19644668. doi:10.1007/s00125-009-1468-7

Use of focus groups to develop methods to communicate cardiovascular disease risk and potential for risk reduction to people with type 2 diabetes
Price HC, Dudley C, Barrow B, Kennedy IA, Griffin SJ, Holman RR
Family Practice 2009;26:351-358. Published:Oct-2009. Epub:21-Jun-2009. PMID:19546119. doi:10.1093/fampra/cmp041
[Abstract]

Presenting the results of clinical trials to participants
Julie L Darbyshire, Rury R Holman and Hermione C Price
Clin Med (Lond). 2009;9:415-416. Published:Oct-2009. PMID:19886097. doi:10.7861/clinmedicine.9-5-415

Cardiovascular disease risk estimation: Why, when and how?
Price HC
Diabetes and Primary Care 2009;11:218-223. Published:Aug-2009
[Full text]

International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes
Nathan DM, Balkau B, Bonora E, Borch-Johnsen K, Buse JB, Colagiuri S, Davidson MB, DeFronzo R, Genuth S, Holman R, Linong Ji, Kirkman S, Knowler WC, Schatz D, Shaw J, Sobngwi E, Steffes M, Vaccaro O, Wareham N, Zinman B, Kahn R
Diabetes Care 2009;32:1327-1334. Published:Jul-2009. Epub:05-Jun-2009. PMID:19502545. doi:10.2337/dc09-9033

Limitations of Existing Diabetes Treatment
Holman RR
Novo Nordisk Annual Report 2009;30. Published:24-Jun-2009

Follow-up of Intensive Glucose Control in Type 2 Diabetes - Authors' reply
Holman RR, Matthews DM, Neil HAW
N Eng J Med 2009;360:418. Published:24-Jun-2009. PMID:19164195. doi:10.1056/NEJMc082275

Predicting 6-year mortality risk in patients with type 2 diabetes: response to Wells et al.
Paul S, Coleman RL, Price HC, Farmer AJ
Diabetes Care 2009;32:e60. Published:May-2009. PMID:19407070. doi:10.2337/dc09-0183
[Abstract]

European physicians overestimate life expectancy and the likely impact of interventions in individuals with Type 2 diabetes
Price HC, Thorne KI , Dukat A, Kellett J
Diab Med. 2009;26:453-455. Published:Apr-2009. Epub:27-Feb-2009. PMID:19388980. doi:10.1111/j.1464-5491.2009.02702.x

Performance of the UKPDS Risk Engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort
Simmons RK, Coleman RL, Price HC, Holman RR, Khaw K, Wareham NJ, Griffin SJ
Diabetes Care 2009;32:708-713. Published:Apr-2009. Epub:29-Dec-2008. PMID:19114615. doi:10.2337/dc08-1918
[Abstract]

Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?
Price HC, Holman RR
Nature Clinical Practice Cardiovasc Medicine 2009;6:168-169. Published:Mar-2009. Epub:20-Jan-2009. PMID:19153560. doi:10.1038/ncpcardio1446
[Abstract]

Impact of using a non-diabetes-specific risk calculator on eligibility for statin therapy in type 2 diabetes
Price HC, Coleman RL, Stevens RJ, Holman RR
Diabetologia 2009;52:394-397. Published:Mar-2009. Epub:02-Dec-2008. PMID:19048226. doi:10.1007/s00125-008-1231-5
[Abstract]

Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial
A J Farmer , A N Wade, D P French, J Simon, P Yudkin, A Gray, A Craven, L Goyder, R R Holman, D Mant, A-L Kinmonth, H A W Neil; DiGEM Trial Group
Health Technology Assessment 2009;13:1-71. Published:Mar-2009. PMID:19254484. doi:10.3310/hta13150

Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes
Hartweg J, Farmer AJ, Holman RR, Neil A
Curr Opin Lipidol 2009;20:30-38. Published:Feb-2009. PMID:19133409. doi:10.1097/MOL.0b013e328321b3be

Community Cardiology Clinics for Secondary Prevention of Coronary Heart Disease and Heart Failure in Primary Care
Khunti K, MD, Stone M, Paul S, Squire I.
Cardiology Review 2009;25:64-67. Published:05-Jan-2009
[Full text]

Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial
Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA on behalf of the AFORRD study group
Diabetologia 2009;52:50-59. Published:Jan-2009. Epub:11-Nov-2008. PMID:19002433. doi:10.1007/s00125-008-1179-5
[Abstract]

Prevalence of Glucokinase (GCK) Mutations in Individuals Screened for Fasting Hyperglycaemia
Gloyn AL, van de Bunt M, Stratton IM, Lonie L, Tucker L, Ellard S, Holman RR
Diabetologia 2009;52:172-174. Published:Jan-2009. Epub:11-Nov-2008. PMID:19002431. doi:10.1007/s00125-008-1188-4

Medical Management of Hyperglycemia in Type 2 Diabetes: a Consensus Algorithm for the Initiation and Adjustment of Therapy
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B
Diabetes Care 2009;32:193-203. Published:Jan-2009. Epub:22-Oct-2008. PMID:18945920. doi:10.2337/dc08-9025
[Abstract]

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B
Diabetologia 2009;52:17-30. Published:Jan-2009. Epub:22-Oct-2008. PMID:18941734. doi:10.1007/s00125-008-1157-y

Changing diabetes by improving control: Outcome trials
Holman RR
Journal of Diabetes Nursing 2009;13:39. Published:Jan-2009

The cost-effectiveness a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care
D A Turner, S Paul, M A Stone, A Juarez-Garcia, I Squire, K Khunti
Heart 2008;94:1601-1606. Published:Dec-2008. Epub:01-May-2008. PMID:18450843. doi:10.1136/hrt.2007.125708
[Abstract]

Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trial
Fiona Turnbull, Mark Woodward, Bruce Neal, Federica Barzi, Toshiharu Ninomiya, John Chalmers, Vlado Perkovic, Nicole Li, S MacMahon and the Blood Pressure Lowering Treatment Trialists’ Collaboration
European Heart Journal 2008;29:2669-2680. Published:Nov-2008. Epub:13-Oct-2008. PMID:18852183. doi:10.1093/eurheartj/ehn427

Analysis of bedside entertainment services' effect on post cardiac surgery physical activity: a prospective, randomised clinical trial
Sotiris Papaspyros, Shitansu Uppal, Shakeeb A. Khan, Sanjoy Paul, David J. O'Regan
European Journal of Cardiothoracic Surgery 2008;34:1022-1026. Published:Nov-2008. Epub:15-Aug-2008. PMID:18706826. doi:10.1016/j.ejcts.2008.05.042
[Abstract]

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Rury R. Holman, Sanjoy K. Paul, M. Angelyn Bethel, David R. Matthews and H. Andrew W. Neil
N Eng J Med 2008;359:1577-89. Published:09-Oct-2008. Epub:10-Sep-2008. PMID:18784090. doi:10.1056/nejmoa0806470
[Slides]

Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes
Rury R. Holman, Sanjoy K. Paul, M. Angelyn Bethel, H. Andrew W. Neil and David R. Matthews
N Eng J Med 2008;359:1565-76. Published:09-Oct-2008. Epub:10-Sep-2008. PMID:18784091. doi:10.1056/nejmoa0806359
[Slides]

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
Robert M. Califf, Mitradev Boolell, Steven M. Haffner, M. Angelyn Bethel, John McMurray, Anil Duggal, Rury R. Holman, for the NAVIGATOR Study Group
Am Heart J 2008;156:623-32. Published:Oct-2008. Epub:09-Sep-2008. PMID:18946890. doi:10.1016/j.ahj.2008.05.017

Determining the most appropriate components for a composite clinical trial outcome
M. Bethel, R. Holman, S. Haffner, R. Califf, A. Huntsman-Labed, T. Hua, J. McMurray
Am Heart J 2008;156:633-40. Published:Oct-2008. Epub:31-Jul-2008. PMID:18926145. doi:10.1016/j.ahj.2008.05.018

Impact of comorbid diabetes on quality of life and perception of angina pain in people with angina registered with general practitioners in the UK
Stone MA, Khunti K, Squire I, Paul S
Qual Life Res 2008;17:887-894. Published:Aug-2008. Epub:17-Jun-2008. PMID:18560992. doi:10.1007/s11136-008-9363-0

The impact of individualised cardiovascular disease (CVD) risk estimates and lifestyle advice on physical activity in individuals at high risk of CVD. A Pilot 2x2 Factorial understanding risk trial
Hermione C Price, Lynne Tucker, Simon J Griffin and Rury R Holman
Cardiovascular Diabetology 2008;7:21. Published:17-Jul-2008. PMID:18637168. doi:10.1186/1475-2840-7-21
[Abstract]

Predictability of price of tea from sensory assessments and biochemical information using data-mining techniques
Sanjoy K Paul
J Sci Food Agric 2008;88:1354-1362. Published:Jun-2008. Epub:09-Apr-2008. doi:10.1002/jsfa.3223

Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial
DREAM Trial Investigators; G.R. Dagenais, H.C. Gerstein, R. Holman, A. Budaj, A. Escalante, T. Hedner, M. Keltai, E. Lonn, S. McFarlane, M. McQueen, K. Teo, P. Sheridan, J. Bosch, J. Pogue, S. Yusuf
Diabetes Care 2008;31:1007-1014. Published:May-2008. Epub:11-Feb-2008. PMID:18268075. doi:10.2337/dc07-1868
[Abstract]

Rosiglitazone Associated Fractures in Type 2 Diabetes:an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
Steven E. Kahn, Bernard Zinman, John M. Lachin, Steven M. Haffner, William H. Herman, Rury R. Holman, Barbara G. Kravitz, Dahong Yu, Mark A. Heise, R. Paul Aftring, Giancarlo Viberti, and for the A Diabetes Outcome Progression Trial (ADOPT) Study Group
Diabetes Care 2008;31:845-851. Published:May-2008. Epub:25-Jan-2008. PMID:18223031. doi:10.2337/dc07-2270
[Abstract]

Addition of Insulin to Oral Therapy in Type 2 Diabetes - Author's reply
Holman RR
N Eng J Med 2008;358:1198. Published:13-Mar-2008. PMID:18337612. doi:10.1056/NEJMc073240

Clinical decisions. Management of type 2 diabetes
Ronald B. Goldberg, Rury Holman, Daniel J. Drucker
N Eng J Med 2008;358:293-7. Published:17-Jan-2008. PMID:18199869. doi:10.1056/NEJMclde0708469

Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones
D. M. Nathan, J. B. Buse, M. B. Davidson, E. Ferrannini, R. R. Holman, R. Sherwin and B. Zinman
Diabetologia 2008;51:8-11. Published:07-Jan-2008. Epub:20-Nov-2007. PMID:18026926. doi:10.1007/s00125-007-0873-z
Erratum in :
Diabetologia 2008;51:522, Print:Mar-2008, doi:10.1007/s00125-007-0917-4

Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones
David M. Nathan, John B. Buse, Mayer B. Davidson, Ele Ferrannini, Rury R. Holman, Robert Sherwin and Bernard Zinman
Diabetes Care 2008;31:173-175. Published:Jan-2008. Epub:22-Oct-2008. PMID:18165348. doi:10.2337/dc08-9016

UKPDS - The first 30 years
Holman RR, Watkins PJ
Diab Med. 2008;25 (Suppl. 2):1

Recommendations for designing tables that report randomized trials
E. S. Johnson, I. M. Stratton
Diab Med. 2007;24:1309-1312. Published:Dec-2007. Epub:01-Nov-2007. PMID:17976200. doi:10.1111/j.1464-5491.2007.02301.x

Cardiovascular Benefits of Metformin
Holman RR
in Metformin - The Gold Standard, Editors CJ Bailey, IW Campbell, JC Chan, JA Davidson, HCS Howlett, P Ritz 2007;15. Published:28-Nov-2007

Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78
Carole A. Cull, Christine C. Jensen, Ravi Retnakaran and Rury R. Holman
Circulation 2007;116:2119-2126. Published:06-Nov-2007. Epub:22-Oct-2007. PMID:17967769. doi:10.1161/CIRCULATIONAHA.107.733428
[Abstract]

Disease management programme for secondary prevention of coronary heart disease and heart failure in primary care: a cluster randomised controlled trial
Kamlesh Khunti, Margaret Stone, Sanjoy Paul, Jan Baines, Louise Gisborne, Azhar Farooqi, Xiujie Luan and Iain Squire
Heart 2007;93:1398-1405. Published:Nov-2007. Epub:19-Feb-2007. PMID:17309907. doi:10.1136/hrt.2006.106955
[Abstract]

Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Rury R. Holman, Kerensa I. Thorne, Andrew J. Farmer, Melanie J. Davies, Joanne F. Keenan, Sanjoy Paul, Jonathan C. Levy for the 4-T Study Group
N Eng J Med 2007;357:1716-30. Published:25-Oct-2007. Epub:21-Sep-2007. PMID:17890232. doi:10.1056/NEJMoa075392
[Abstract] [Slides]

Stability of soluble adhesion molecules, selectins and C-reactive protein at various temperatures: implications for epidemiological and large-scale clinical studies
Janine Hartweg, Michael Gunter, Rafael Perera, Andrew Farmer, Carole Cull, Casper Schalkwijk, Astrid Kok, Harry Twaalfhoven, Rury Holman and Andrew Neil
Clinical Chemistry 2007;53:1858-60. Published:Oct-2007. Epub:03-Aug-2007. PMID:17675341. doi:10.1373/clinchem.2006.076380

GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77.
M. Desai, C. A. Cull, V. A. Horton, M. R. Christie, E. Bonifacio, V. Lampasona, P. J. Bingley, J. C. Levy, I. R. Mackay, P. Zimmet, R. R. Holman and A. Clark
Diabetologia 2007;50:2052-2060. Published:Oct-2007. Epub:27-Jul-2007. PMID:17657474. doi:10.1007/s00125-007-0745-6

Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes
J. Hartweg, A. J. Farmer, R. Perera1, R. R. Holman and H. A. W. Neil
Diabetologia 2007;50:1593-1602. Published:Aug-2007. Epub:31-May-2007. PMID:17541540. doi:10.1007/s00125-007-0695-z

Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial
Andrew Farmer, Alisha Wade, Elizabeth Goyder, Patricia Yudkin, David French, Anthea Craven, Rury Holman, Ann-Louise Kinmonth, Andrew Neil on behalf of the Diabetes Glycaemic Education and Monitoring Trial Group
BMJ 2007;335:132-6. Published:21-Jul-2007. Epub:25-Jun-2007. PMID:17591623. doi:10.1136/bmj.39247.447431.BE

Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting
The Mount Hood 4 Modeling Group
Diabetes Care 2007;30:1638-1646. Published:Jun-2007. PMID:17526823. doi:10.2337/dc07-9919

Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes
Ruth L. Coleman, Richard J. Stevens, Ravi Retnakaran, and Rury R. Holman
Diabetes Care 2007;30:1292-1293. Published:May-2007. Epub:08-Feb-2007. PMID:17290036. doi:10.2337/dc06-1358

Role of Lifestyle and Oral Anti Diabetic Agents to Prevent Type 2 Diabetes Mellitus and Cardiovascular Disease
M.Angelyn Bethel, Robert M. Califf
American Journal of Cardiology 2007;99:726-731. Published:01-Mar-2007. Epub:10-Jan-2007. PMID:17317381. doi:10.1016/j.amjcard.2006.09.122

Factors predictive of voiding problems following insertion of tension-free vaginal tape
A. Shukla, S. Paul, A. Nishtar, J. Bibby
Int J Gynaecol Obstet. 2007;96:122-126. Published:Feb-2007. Epub:18-Jan-2007. PMID:17239884. doi:10.1016/j.ijgo.2006.10.013
[Abstract]

Meta-analysis of the effects of omega-3 poylunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes
J. Hartweg, A. J. Farmer, R. R. Holman and H. A. W. Neil
Diabetologia 2007;50:250-258. Published:27-Jan-2007. Epub:21-Nov-2006. PMID:17119918. doi:10.1007/s00125-006-0486-y
[Abstract]

An association analysis of the HLA gene region in latent autoimmune diabetes in adults
M. Desai, E. Zeggini, V. A. Horton, K. R. Owen, A. T. Hattersley, J. C. Levy, M. Walker, K. M. Gillespie, P. J. Bingley, G. A. Hitman, R. R. Holman, M. I. McCarthy and A. Clark
Diabetologia 2007;50:68-73. Published:Jan-2007. Epub:02-Dec-2006. PMID:17143607. doi:10.1007/s00125-006-0513-z
[Abstract]

Metformin as First Choice in oral Diabetes Treatment: the UKPDS experience
Holman R
Journ Annu Diabetol Hotel Dieu 2007;13:13-20. Published:Jan-2007. PMID:18613325
[Full text]

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G for the ADOPT Study Group
N Eng J Med 2006;355:2427-43. Published:07-Dec-2006. Epub:04-Dec-2006. PMID:17145742. doi:10.1056/NEJMoa066224
[Abstract] [Slides]
Erratum in :
N Eng J Med 2007;356:1387-8, Print:29-Mar-2007, doi:10.1056/NEJMx070014

A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe
Viberti G, Lachin J, Holman R, Zinman B, Haffner S, Kravitz B, Heise MA, Jones NP, O'Neill MC, Freed MI, Kahn SE, Herman WH for the ADOPT Study Group
Diab Med. 2006;23:1289-1294. Published:Dec-2006. Epub:17-Nov-2006. PMID:17116177. doi:10.1111/j.1464-5491.2006.02022.x
[Abstract]

Paraoxonase2 (PON2) Polymorphisms and Development of Renal Dysfunction in Type 2 Diabetes: UKPDS 76
Calle R, McCarthy MI, Banerjee P, Zeggini E, Cull CA, Thorne KI, Wiltshire S, Terra S, Meyer D, Richmond J, Mancuso J, Milos P, Fryburg D, Holman RR
Diabetologia 2006;49:2892-2899. Published:Dec-2006. Epub:03-Oct-2006. PMID:17096118. doi:10.1007/s00125-006-0436-8
[Abstract]

Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS 73
Wright AD, Cull CA, Macleod KM, Holman RR for the UKPDS Group
J Diabetes Complications 2006;20:402-408. Published:Nov-2006. Epub:25-Oct-2006. PMID:17070446. doi:10.1016/j.jdiacomp.2005.08.010
[Abstract]

A Clinical Screening Tool Identifies Autoimmune Diabetes in Adults: Response to Fourlanos et al.
Timothy M.E. Davis, Carole A. Cull and Rury R. Holman
Diabetes Care 2006;29:2560. Published:Nov-2006. PMID:17065707. doi:10.2337/dc06-1321

Effect of Ramipril on the Incidence of diabetes
Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR for the DREAM Trial Investigators
N Eng J Med 2006;355:1551-62. Published:12-Oct-2006. Epub:15-Sep-2006. PMID:16980380. doi:10.1056/NEJMoa065061

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial
Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR on behalf of the DREAM trial investigators
Lancet 2006;368:1096-105. Published:15-Sep-2006. Epub:20-Sep-2006. PMID:16997664. doi:10.1016/S0140-6736(06)69420-8
Erratum in :
Lancet 2006;368:1770

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B
Diabetes Care 2006;29:1963-1972. Published:Aug-2006. Epub:27-Jun-2006. PMID:16873813. doi:10.2337/dc06-9912
Erratum in :
Diabetes Care 2006;49:2816-8, Print:Nov-2006

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B
Diabetologia 2006;49:1711-1721. Published:Aug-2006. Epub:27-Jun-2006. PMID:16802130. doi:10.1007/s00125-006-0316-2
Erratum in :
Diabetologia 2006;49:2816-2818, Print:Nov-2006, Epub:13-Sep-2006, doi:10.1007/s00125-006-0415-0

Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75)
Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR
Diabetologia 2006;49:1761-1769. Published:Aug-2006. Epub:31-May-2006. PMID:16736131. doi:10.1007/s00125-006-0297-1
[Abstract]

Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes
Kahn SE, Zinman B, Haffner SM, O'Neill MC, Kravitz BG, Yu D, Freed MI, Herman WH, Holman RR, Jones NP, Lachin JM, Viberti GC and the ADOPT Study Group
Diabetes 2006;55:2357-2364. Published:Aug-2006. PMID:16873701. doi:10.2337/db06-0116
[Abstract]

Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials
Stettler C, Allemann S, Jüni P, Cull CA, Holman RR, Egger M, Krähenbühl S, Diem P
American Heart Journal 2006;152:27-38. Published:Jul-2006. Epub:13-Jul-2006. PMID:16824829. doi:10.1016/j.ahj.2005.09.015
[Abstract]

Axillary and tympanic membrane temperature measurements are unreliable early after cardiopulmonary bypass
Khan TA, Vohra HA, Paul S, Rosin MD, Patel RL
European Journal of Anaesthesiology 2006;23:551-554. Published:Jul-2006. Epub:27-Jan-2006. PMID:16438760. doi:10.1017/S0265021505001936
[Abstract]

Assessing the Impact of Visual Acuity on Quality of Life in Individuals With Type 2 Diabetes Using the Short Form-36
Clarke PM, Simon J, Cull CA, Holman RR
Diabetes Care 2006;29:1506-1511. Published:Jul-2006. PMID:16801570. doi:10.2337/dc05-2150
[Abstract]

Risk Factors for Renal Dysfunction in Type 2 Diabetes
Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR for the UKPDS study group
Diabetes 2006;55:1832-1839. Published:Jun-2006. PMID:16731850. doi:10.2337/db05-1620
[Abstract]

The Variable Number of Tandem Repeats Upstream of the Insulin Gene Is a Susceptibility Locus for Latent Autoimmune Diabetes in Adults
Desai M, Zeggini E, Horton VA, Owen KR, Hattersley AT, Levy JC, Hitman GA, Walker M, Holman RR, McCarthy MI, Clark A
Diabetes 2006;55:1890-1894. Published:Jun-2006. PMID:16731859. doi:10.2337/db06-0089
[Abstract]

Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective
Holman RR
Metabolism Clinical and Experimental 2006;55 (Suppl 1):S2-S5. Published:May-2006. PMID:16631806. doi:10.1016/j.metabol.2006.02.006
[Abstract]

PROactive Study
Holman RR, Retnakaran R, Farmer A, Stevens RJ
Lancet 2006;367:25-26. Published:07-Jan-2006. Epub:05-Jan-2006. PMID:16399144. doi:10.1016/S0140-6736(06)67914-2

A common mitchondrial DNA variant is associated with thinness in mothers and their 20 year old offspring
Parker E, Phillips DI, Cockington RA, Cull C, Poulton J
American Journal of Physiology, Endocrinology & Metabolism 2005;289:E1110-E1114. Published:Dec-2005. Epub:05-Jul-2005. PMID:15998658. doi:10.1152/ajpendo.00600.2004
[Abstract]

Reporting of diabetes on death certificates using data from the UK Prospective Diabetes Study
Thomason MJ, Biddulph JP, Cull CA, Holman RR
Diab Med. 2005;22:1031-1036. Published:Aug-2005. Epub:02-Mar-2005. PMID:16026369. doi:10.1111/j.1464-5491.2005.01584.x

Non-HDL Cholesterol is less informative than the total-to-HDL cholesterol ratio in predicting cardiovascular risk in type 2 diabetes
Holman RR, Coleman RL, Shine BS, Stevens RJ
Diabetes Care 2005;28:1796-1797. Published:Jul-2005. PMID:15983339. doi:10.2337/diacare.28.7.1796

Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)
Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR
Diabetologia 2005;48:868-877. Published:May-2005. Epub:15-Apr-2005. PMID:15834550. doi:10.1007/s00125-005-1717-3

Glycemic Control Continues to Deteriorate After Sulfonylureas Are Added to Metformin Among Patients With Type 2 Diabetes
Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR
Diabetes Care 2005;28:995-1000. Published:May-2005. PMID:15855556. doi:10.2337/diacare.28.5.995
[Abstract]

IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes
G. F. Bottazzo, E. Bosi, C. A. Cull, E. Bonifacio, M. Locatelli, P. Zimmet, I. R. Mackay, R. R. Holman
Diabetologia 2005;48:703-708. Published:Apr-2005. Epub:12-Mar-2005. PMID:15765222. doi:10.1007/s00125-005-1691-9
Erratum in :
Diabetologia 2005;48:1240, Epub:19-May-2005, doi:10.1007/s00125-005-1808-1

Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control
T. M. E. Davis, A. D. Wright, Z. M. Mehta, C. A. Cull, I. M. Stratton, G. F. Bottazzo, E. Bosi, I. R. Mackay, R. R. Holman
Diabetologia 2005;48:695-702. Published:Apr-2005. Epub:24-Feb-2005. PMID:15729570. doi:10.1007/s00125-005-1690-x

Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67)
Adler AI, Levy JC, Matthews DR, Stratton IM, Hines G, Holman RR
Diab Med. 2005;22:306-311. Published:Mar-2005. Epub:02-Dec-2004. PMID:15717879. doi:10.1111/j.1464-5491.2004.01418.x
[Abstract]

Framingham risk equations underestimate coronary heart disease risk in diabetes
R. J. Stevens, R. L. Coleman, R. R. Holman
Diab Med. 2005;22:228. Published:Feb-2005. Epub:19-Jan-2005. PMID:15660747. doi:10.1111/j.1464-5491.2005.01387.x

Changing aspirin use in patients with Type 2 diabetes in the UKPDS
Cull CA, Neil HAW, Holman RR
Diab Med. 2004;21:1368-1371. Published:Dec-2004. Epub:24-Nov-2004. PMID:15569143. doi:10.1111/j.1464-5491.2004.01328.x
[Abstract]

Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus
Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM for the UK Prospective Diabetes Study Group
Archives of Ophthalmology 2004;122:1631-1640. Published:Nov-2004. PMID:15534123. doi:10.1001/archopht.122.11.1631

A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS 68)
P. M. Clarke, A. M. Gray, A. Briggs, A. J. Farmer, P. Fenn, R. J. Stevens, D. R. Matthews, I. M. Stratton, R. R. Holman
Diabetologia 2004;47:1747-1759. Published:Oct-2004. Epub:27-Oct-2004. PMID:15517152. doi:10.1007/s00125-004-1527-z

Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial
Gerstein HC, Yusuf S, Holman RR, Bosch J, Pogue J; The DREAM Trial Investigators
Diabetologia 2004;47:1519-1527. Published:Sep-2004. Epub:21-Aug-2004. PMID:15322749. doi:10.1007/s00125-004-1485-5
[Abstract]

Guidelines for computer modeling of diabetes and its complications
Bergemann R, Brown J, Chan W, Clarke P, Eddy D, Herman W, Palmer AJ, Roze S, Stevens R, Zhang P
Diabetes Care 2004;27:2262-2265. Published:Sep-2004. PMID:15333499. doi:10.2337/diacare.27.9.2262

A standardized triglyceride and carbohydrate challenge: response to thanopoulou, karamanos, and roussi
Mohanlal N, Holman RR
Diabetes Care 2004;27:2093. Published:Aug-2004. PMID:15277456. doi:10.2337/diacare.27.8.2093

Comparative study of prognostic value for coronary disease risk between the U.K. Prospective diabetes study and framingham models: response to Protopsaltis et al.
Stevens RJ, Holman RR
Diabetes Care 2004;27:1844-1845. Published:Jul-2004. PMID:15220283. doi:10.2337/diacare.27.7.1843

A standardized triglyceride and carbohydrate challenge: the oral triglyceride tolerance test
Nina Mohanlal and Rury R. Holman
Diabetes Care 2004;27:89-94. Published:Jan-2004. PMID:14693972. doi:10.2337/diacare.27.1.89
[Abstract]

Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66
Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR
Diabetes Care 2004;27:201-207. Published:Jan-2004. PMID:14693990. doi:10.2337/diacare.27.1.201
[Abstract]

Evaluation of methods for interval estimation of model outputs, with application to survival models
Stevens RJ
Journal of Applied Statistics 2003;30:967-981. Published:Sep-2003. doi:10.1080/0266476032000076100

Poor pregnancy outcome for women with Type 2 diabetes
Hadden DR, Cull CA, Croft DJ, Holman RR
Diab Med. 2003;20:506-507. Published:Jun-2003. Epub:18-Jul-2003. PMID:12786690. doi:10.1046/j.1464-5491.2003.00955_2.x

The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No 65)
Clarke P, Gray A, Legood R, Briggs A, Holman R
Diab Med. 2003;20:442-450. Published:Jun-2003. Epub:18-Jul-2003. PMID:12786677. doi:10.1046/j.1464-5491.2003.00972.x

Autoantibodies to the islet cell antigen SOX-13 areassociated with duration but not type of diabetes
Davis TM, Mehta Z, Mackay IR, Cull CA, Bruce DG, Fida S, Rowley MJ, Holman RR
Diab Med. 2003;20:198-204. Published:Mar-2003. Epub:10-Mar-2003. PMID:12675663. doi:10.1046/j.1464-5491.2003.00897.x
[Abstract]

Intensive control policies for blood pressure and blood glucose concentration in type 2 diabetes are affordable in England
Gray A, Clarke P, Farmer A, Holman RR
Evidence-based Healthcare 2003;7:51-52. Published:Mar-2003. Epub:10-Mar-2003. doi:10.1016/S1462-9410(02)00133-X

Diabetes education and knowledge in patients with type 2 diabetes from the community The Fremantle Diabetes Study
Bruce DG, Davis WA, Cull CA, Davis TM
J Diabetes Complications 2003;17:82-89. Published:Mar-2003. PMID:12614974. doi:10.1016/S1056-8727(02)00191-5

Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)
Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR for the UKPDS Group
Kidney International 2003;63:225-232. Published:Jan-2003. PMID:12472787. doi:10.1046/j.1523-1755.2003.00712.x
[Abstract]

Fire-and-forget in prevention of coronary heart disease
Karpe F, Holman R.
Lancet 2002;360:1984. Published:14-Dec-2002. Epub:13-Dec-2002. PMID:12493308. doi:10.1016/S0140-6736(02)11890-3

Modeling glucose exposure as a risk factor for photocoagulation in type 2 diabetes.
Stevens RJ, Stratton IM, Holman RR.
J Diabetes Complications 2002;16:371-376. Published:Nov-2002. Epub:04-Dec-2002. PMID:12477619. doi:10.1016/S1056-8727(02)00161-7
[Abstract]

International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling of 2143 patients with ruptured intracranial aneurysms: a randomised trial
Molyneux A, Kerr R; International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group, Stratton I, Sandercock P, Clarke M, Shrimpton J, Holman R
J Stroke Cerebrovasc Dis. 2002;11:304-14. Published:Nov-2002. PMID:17903891. doi:10.1053/jscd.2002.130390

International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling of 2143 patients with ruptured intracranial aneurysms: a randomised trial
Molyneux A, Kerr R, Stratton I, Sandercock P, Clarke M, Shrimpton J, Holman R; International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group
Lancet 2002;360:1267-1274. Published:26-Oct-2002. PMID:12414200. doi:10.1016/S0140-6736(05)67214-5
[Abstract]

The economics of translating trial evidence into practice: costs of implementing more intensive glycaemic and blood pressure control in type 2 diabetes in England
Gray A, Clarke P, Farmer A, Holman R for the United Kingdom Prospective Diabetes Study (UKPDS) Group
BMJ 2002;325:860. Published:19-Oct-2002. PMID:12386035. doi:10.1136/bmj.325.7369.860
[Abstract]

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes
Viberti G. Kahn SE. Greene DA. Herman WH. Zinman B. Holman RR. Haffner SM. Levy D. Lachin JM. Berry RA. Heise MA. Jones NP. Freed MI.
Diabetes Care 2002;25:1737-1743. Published:Oct-2002. PMID:12351470. doi:10.2337/diacare.25.10.1737
[Abstract]

Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis
The Homocysteine Studies Collaboration
JAMA 2002;288:2015-2023. Published:Oct-2002. PMID:12387654. doi:10.1001/jama.288.16.2015

Are Lower Fasting Plasma Glucose Levels at Diagnosis of Type 2 Diabetes Associated with Improved Outcomes?
Colagiuri S, Cull CA, Holman RR
Diabetes Care 2002;25:1410-1417. Published:Aug-2002. PMID:12145243. doi:10.2337/diacare.25.5.894
[Abstract]

Estimating utility values for health states of type 2 diabetic patients using the EQ-5D
Clarke P, Gray A, Holman R
Medical Decision Making 2002;4:340-349. Published:Aug-2002. PMID:12150599. doi:10.1177/0272989X0202200412

Risk of Stroke in Type 2 Diabetes Estimated by the UK Prospective Diabetes Study Risk Engine
Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, Holman RR
Stroke 2002;33:1776-1781. Published:Jul-2002. PMID:12105351. doi:10.1161/01.STR.0000020091.07144.C7
[Abstract]

Prevention Conference VI: Diabetes and Cardiovascular Disease
Grundy SM, Garber A, Goldberg R, Havas S, Holman R, Lamendola C, Howard WJ, Savage P, Sowers J, Vega GL
Circulation 2002;105:e153. Published:07-May-2002. PMID:11994266. doi:10.1161/01.CIR.0000014022.85836.96

A non-invasive frequent home blood glucose monitor
Lenzen H, Barrow BA, White S, Holman RR.
Practical Diabetes 2002;19:101-103. Published:May-2002. Epub:28-May-2002. doi:10.1002/pdi.312
[Abstract]

Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling
Herlihy OM, Barrow BA, Grant PJ, Levy JC
Diabetologia 2002;45:635-641. Published:May-2002. Epub:26-Apr-2002. PMID:12107743. doi:10.1007/s00125-002-0795-8
[Abstract]

Hyperglycemia and Other Potentially Modifiable Risk Factors for Peripheral Vascular Disease in Type 2 Diabetes.
Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR
Diabetes Care 2002;25:894-899. Published:May-2002. PMID:11978687. doi:10.2337/diacare.25.5.894
[Abstract]

Human calcium/calmodulin-dependent protein kinase II gamma gene (CAMK2G): cloning, genomic structure and detection of variants in subjects with type II diabetes
Gloyn AL, Desai M, Clark A, Levy JC, Holman RR, Frayling TM, Hattersley AT, Ashcroft SJH
Diabetologia 2002;45:58-583. Published:Apr-2002. PMID:12032636. doi:10.1007/s00125-002-0779-8
[Abstract]

Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57)
Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR.
Diabetes Care 2002;25:330-336. Published:Feb-2002. PMID:11815505. doi:10.2337/diacare.25.2.330
[Abstract]
Erratum in :
Diabetes Care 2002;25:1268, Print:Jul-2002, doi:10.2337/diacare.25.7.1268

Standardization of glycated haemoglobin
Marshall SM, Home PD, Manley SM, Barth JH, John WG.
Annals of Clinical Biochemistry 2002;39:77-79. Published:Jan-2002. PMID:11853199

Analysis of the United Kingdom Prospective Diabetes Study
Holman RR
Endocrine Practice 2002;8 Supplement 1:33-34. Published:Jan-2002. doi:10.4158/EP.8.S1.33
[Abstract]

Calculation of coronary risk in Type II diabetes: another cause for concern: authors' reply
Holman RR, Manley SE, Stevens RJ on behalf of the UKPDS Study Group
Clin Sci (Lond). 2002;103:217-219. Published:01-Aug-2001. PMID:12149114. doi:10.1042/cs1030217v

The UKPDS: implications for the dyslipidaemic patient
Holman R
Acta Diabetologica 2001;38 Suppl 1:S9-S14. Published:Sep-2006. PMID:11829452. doi:10.1007/s005920170003
[Abstract]

The UKPDS Risk Engine: a model for the risk of coronary heart disease in type 2 diabetes
Richard J. STEVENS, Viti KOTHARI, Amanda I. ADLER, Irene M. STRATTON and Rury R. HOLMAN on behalf of the United Kingdom Prospective Diabetes Study (UKPDS) Group
Clin Sci (Lond). 2001;101:671-679. Published:Dec-2001. PMID:11724655. doi:10.1042/cs1010671
[Abstract]
Erratum in :
Clin Sci (Lond). 2002;102:679, Print:Jun-2002, doi:10.1042/cs1020679

Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies.
Clarke R, Lewington S, Donald A, Johnston C, Refsum H, Stratton IM, Jacques P, Breteler MMB, Holman R
Journal of Cardiovascular Risk 2001;8:363-369. Published:Dec-2001. PMID:11873092. doi:10.1177/174182670100800605
[Abstract]

Butyrylcholinesterase K variant on chromsome 3q is associated with Type II diabetes in white Caucasian subjects
Hashim Y, Shepherd D, Wiltshire S, Holman RR, Levy JC, Clark A, et al.
Diabetologia 2001;44:2227-2230. Published:Dec-2001. PMID:11793025. doi:10.1007/s001250100033
[Abstract]
Erratum in :
Diabetologia 2002;45:459, Print:Mar-2002

Relationship between ethnicity and glycaemic control, lipid profiles and blood pressure during the first nine years of Type 2 diabetes
Davis TM, Cull CA, Holman RR; U.K. Prospective Diabetes Study (UKPDS) Group
Diabetes Care 2001;24:1167-1173. Published:Jul-2001. PMID:11423497. doi:10.2337/diacare.24.7.1167
[Abstract]

An economic evaluation of atenolol versus captopril in patients with Type 2 diabetes (UKPDS 54)
Gray A, Clarke P, Raikou M, Stevens R, Neil A, Cull C, Stratton I, Holman R
Diab Med. 2001;18:438-444. Published:Jun-2001. Epub:20-Dec-2001. PMID:11472461. doi:10.1046/j.1464-5491.2001.00485.x
[Abstract]

Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53)
Gloyn AL, Hashim Y, Ashcroft SJ, Ashfield R, Wiltshire S, Turner RC.
Diab Med. 2001;18:206-12. Published:Mar-2001. Epub:20-Dec-2001. PMID:11318841. doi:10.1046/j.1464-5491.2001.00449.x
[Abstract]
Erratum in :
Diab Med. 2003;20:252, Print:Mar-2003

Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52)
Kohner EM, Stratton IM, Aldington SJ, Holman RR, Matthews DR.
Diab Med. 2001;18:178-184. Published:Mar-2001. Epub:20-Dec-2001. PMID:11318837. doi:10.1046/j.1464-5491.2001.00458.x
[Abstract]

Cost-effective analysis of intensive blood glucose control with metformin in overweight patients with type 2 diabetes (UKPDS 51).
Clarke P, Gray A, Adler A, Stevens R, Raikou M, Cull C, Stratton I, Holman R; UKPDS Group. United Kingdom Prospective Diabetes Study
Diabetologia 2001;44:298-304. Published:Mar-2001. PMID:11317659. doi:10.1007/s001250051617
[Abstract]

UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis
Stratton IM, Kohner EM, Aldington SJ, Turner RC, Manley SE, Matthews DR
Diabetologia 2001;44:1546-163. Published:Feb-2001. PMID:11270671. doi:10.1007/s001250051594
[Abstract]

Possible prevention of type 2 diabetes with acarbose or metformin
Holman RR, North BV, Tunbridge FK
Diabetes 2000;Suppl 1:1078-1079. Published:12-Apr-2005

Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of propectively designed overviews of randomised trials
MacMahon, N Chapman; Blood Pressure Lowering Treatment Trialists' Collaboration
The Lancet 2000;356:1955-1964. Published:09-Dec-2000. PMID:11130523. doi:10.1016/S0140-6736(00)03307-9
[Abstract]

Life-expectancy projection by modelling and computer simulation (UKPDS 46)
Stevens R, Adler A, Gray A, Briggs A, Holman R.
Diabetes Res Clin Pract. 2000;50 (Suppl 3):S5-S13. Published:Nov-2000. Epub:13-Nov-2000. PMID:11080560. doi:10.1016/S0168-8227(00)00214-X
[Abstract]

Seeing what you want to see in randomised controlled trials. Authors' choice of study was ill informed
Holman RR
British Medical Journal 2000;321:1078-1079. Published:28-Oct-2000. PMID:11053192. doi:10.1136/bmj.321.7268.1078
[Abstract]

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study
Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR
British Medical Journal 2000;321:412-419. Published:12-Aug-2000. PMID:10938049. doi:10.1136/bmj.321.7258.412
[Abstract] [Slides]
Erratum in :
British Medical Journal 2001;322:90, Print:13-Jan-2001

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR
British Medical Journal 2000;321:405-412. Published:12-Aug-2000. PMID:10938048. doi:10.1136/bmj.321.7258.405
[Abstract] [Slides]

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study
Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR
British Medical Journal 2000;321:412-419. Published:12-Aug-2000. PMID:10938049. doi:10.1136/bmj.321.7258.412
[Abstract] [Slides]
Erratum in :
British Medical Journal 2001;322:90, Print:13-Jan-2001

Effects of three months' diet after diagnosis of type 2 diabetes on plasma lipids and lipoproteins
Manley SM, Stratton IM, Cull CA, Fighi V, Eeley EA, Matthews DR, Holman RR, Turner RC
Diab Med. 2000;17:518-23. Published:Jul-2000. PMID:10972581. doi:10.1046/j.1464-5491.2000.00320.x
[Abstract]

Does the choice of treatment for type 2 diabetes affect the physiological response to hypoglycaemia
Peacey SR, Robinson R, Bedford C, Harris ND, MacDonald IA, Holman RR, Heller SR
Diabetes Care 2000;23:1022-1023. Published:Jul-2000. PMID:10895860. doi:10.2337/diacare.23.7.1022

Cost-effective analysis of intensive blood glucose control with metformin in overweight patients with type 2 diabetes.
Gray A, Raikou M, McGuire A, Fenn P, Stevens R, Cull C, Stratton I, Adler A, Holman R, Turner R
British Medical Journal 2000;320:1373-1378. Published:20-May-2000. PMID:10818026. doi:10.1136/bmj.320.7246.1373
[Abstract]

Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial
Gray A, Raikou M, McGurire A, Fenn P, Stevens R, Cull C, Stratton IM, Adler AI, Holman RR, Turner RC
British Medical Journal 2000;320:1373-1378. Published:20-May-2000. PMID:10818026. doi:10.1136/bmj.320.7246.1373

Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47)
Adler AI, Neil AW, Manley SE, Holman RR, Turner RC
Am Heart J 1999;138 (5 Pt 1):S353-9. Published:11-Sep-2006. PMID:10539797. doi:10.1016/S0002-8703(99)70035-9
[Abstract]

Metformin and Risk of Cardiovascular Disease
Turner RC, Holman RR
Cardiology 1999;91:203-204. Published:Sep-1999. Epub:24-Sep-1999. PMID:10516415. doi:10.1159/000006910

Sequence variants of the sarco(endo)plasmic reticulum Ca2+-transport ATPase 3 gene (SERCA3) are associated with Type 2 diabetes in Caucasians
Varadi A, Lebel L, Hashim Y, Mehta Z, Ashcroft SJH, Turner RC
Diabetologia 1999;42:1240-1243. Published:Sep-1999. PMID:10525666. doi:10.1007/s001250051298
[Abstract]

Microaneurysms in the development of diabetic retinopathy
Kohner EM, Stratton IM, Adlington SJ, Turner RC
Diabetologia 1999;42:1107-1112. Published:Sep-1999. PMID:10447523. doi:10.1007/s001250051278
[Abstract]

UKPDS: What was the question? UK Prospective Diabetes Study
Turner R, Holman R, Butterfield J
Lancet 1999;354:600. Published:14-Aug-1999. PMID:10470732. doi:10.1016/S0140-6736(05)77957-5

Randomised, double-blind trial of acarbose in type 2 diabetes shows improved glycaemic control over three years
Holman RR, Cull CA, Turner RC
Diabetes Care 1999;22:960-964. Published:Jul-1999. PMID:10372249. doi:10.2337/diacare.22.6.960
[Abstract]
Erratum in :
Diabetes Care 1999;22:1922, Print:Nov-1999

Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control
UKPDS Group
Diabetes Care 1999;22:1125-1136. Published:Jul-1999. PMID:10388978. doi:10.2337/diacare.22.7.1125
[Abstract]

Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49)
Turner RC, Cull CA, Frighi V, Holman RR
JAMA 1999;281:2005-2012. Published:02-Jun-1999. PMID:10359389. doi:10.1001/jama.281.21.2005
[Abstract]

Risk factors for stroke in non-insulin dependent diabetes mellitus
Davies TME, Millns H, Stratton IM, Holman RR, Turner RC
Arch Intern Med 1999;159:1097-1103. Published:24-May-1999. PMID:10335687. doi:10.1001/archinte.159.10.1097
[Abstract]

Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). UK Prospective Diabetes Study (UKPDS) Group
Horton VA, Stratton IM, Bottazzo GF, Shattock M, MacKay I, Zimmett P, Manley SE, Holman RR, Turner RC
Diabetologia 1999;42:608-616. Published:May-1999. PMID:10333055. doi:10.1007/s001250051202
[Abstract]

Hepatocyte nuclear factor-1alpha (the MODY3 gene) mutations in late onset Type 2 diabetes in the UK.
Cox RD, Sotham L, Hashim Y, Horton V, Mehta Z, Taghavi J, Lathrop M, Turner RC
Diabetes 1999;42:120-121. Published:Jan-1999. PMID:10027593. doi:10.1007/s001250051127

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
UKPDS Group
BMJ 1998;317:703-713. Published:12-Sep-1998. PMID:9732337. doi:10.1136/bmj.317.7160.703
[Abstract]

Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group
UKPDS Group
BMJ 1998;317:713-720. Published:12-Sep-1998. PMID:9732338. doi:10.1136/bmj.317.7160.713
[Abstract]

Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes
UKPDS Group
British Medical Journal 1998;317:720-726. Published:12-Sep-1998. PMID:9732339. doi:10.1136/bmj.317.7160.720
[Abstract]

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
UKPDS Group
Lancet 1998;352:837-853. Published:12-Sep-1998. PMID:9742976. doi:10.1016/S0140-6736(98)07019-6
[Abstract]
Erratum in :
Lancet 1999;354:602, Print:14-Aug-1999

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
UKPDS Group
Lancet 1998;352:854-865. Published:12-Sep-1998. PMID:9742977. doi:10.1016/S0140-6736(98)07037-8
[Abstract]
Erratum in :
Lancet 1998;352:1558, Print:07-Nov-1998, doi:10.1016/S0140-6736(05)60381-9

Ethnicity and cardiovascular disease. The incidence of myocardial infarction in white, South Asian, and Afro-Caribbean patients with type 2 diabetes (U.K. Prospective Diabetes Study 32)
UKPDS Group
Diabetes Care 1998;21:1271-1277. Published:Aug-1998. PMID:9702432. doi:10.2337/diacare.21.8.1271
[Abstract]

Assessing the potential for alpha-glucosidase inhibitors in prediabetic states
Holman RR
Diabetes Res Clin Pract. 1998;40:S21-S25. Published:Jul-1998. Epub:07-Aug-1998. PMID:9740498. doi:10.1016/S0168-8227(98)00038-2
[Abstract]

Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM
Rachman J, Payne MJ, Levy JC, Barrow BA, Holman RR, Turner RC
Diabetes Care 1998;21:810-816. Published:May-1998. PMID:9589246. doi:10.2337/diacare.21.5.810
[Abstract]

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years
Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC
Diab Med. 1998;15:297-303. Published:Apr-1998. PMID:9585394. doi:10.1002/(SICI)1096-9136(199804)15:4<297::AID-DIA572>3.0.CO;2-W
[Abstract]

Risk factors for coronary artery disease in non-insulin dependent diabetes
UKPDS Group
British Medical Journal 1998 1998;316:823-828. Published:14-Mar-1998. PMID:9549452. doi:10.1136/bmj.316.7134.823
[Abstract]

United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors
UKPDS Group
Archives of Ophthalmology 1998;116:297-303. Published:Mar-1998. PMID:9514482. doi:10.1001/archopht.116.3.297
[Abstract]

United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy
UKPDS Group
Annals of internal medicine 1998;128:165-175. Published:01-Feb-1998. PMID:9454524. doi:10.7326/0003-4819-128-3-199802010-00001
[Abstract]

UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes
UKPDS Group
Diabetes Care 1998;21:87-92. Published:Jan-1998. PMID:9538975. doi:10.2337/diacare.21.1.87
[Abstract]

Progressive Hyperglycaemia: the UKPDS Experience
Holman RR
Consultant (Supp) 1997;37:530-536. Published:11-Sep-2006
[Abstract]

Subject Identification and Recruitment for a non-insulin-dependent diabetes prevention trial
Fasting Hyperglycaemia Study group, Hammersley MS, Meyer LC, Morris RJ, Manley SE
Metabolism 1997;46:44-49. Published:Dec-1997. PMID:9439559. doi:10.1016/S0026-0495(97)90317-6
[Abstract]

The Fasting Hyperglycaemia Study: II. Randomized controlled trial of reinforced healthy-living advice in subjects with increased but not diabetic fasting plasma glucose
P A Dyson, M S Hammersley, R J Morris, R R Holman, R C Turner
Metabolism 1997;46:50-55. Published:Dec-1997. PMID:9439560. doi:10.1016/S0026-0495(97)90318-8
[Abstract]

Randomised controlled trial of sulphonylurea therapy for subjects with increased fasting glucose levels
FHS group, Karunakaran S, Hammersley MS, Morris RJ, Turner RC, Holman RR
Metabolism 1997;46:56-60. Published:Dec-1997. PMID:9439561. doi:10.1016/S0026-0495(97)90319-X
[Abstract]

UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes
UKPDS Group
Lancet 1997;350:1288-1293. Published:01-Nov-1997. PMID:9357409. doi:10.1016/S0140-6736(97)03062-6
[Abstract]
Erratum in :
Lancet 1998;351:376, Print:31-Jan-1998, doi:10.1016/S0140-6736(05)78287-8

U.K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex
UKPDS Group
Diabetes Care 1997;20:1683-1687. Published:Nov-1997. PMID:9353608. doi:10.2337/diacare.20.11.1683
[Abstract]

Approach to maintaining comparability of biochemical data during long-term clinical trials
Cull CA, Manley SE, Stratton IM, Neil HAW, Ross IS, Holman RR, Turner RC, Matthews DR
Clinical Chemistry 1997;43:1913-1918. Published:Oct-1997. PMID:9342012
[Full text] [Abstract]

U.K. Prospective Diabetes Study 22. Effect of age at diagnosis on diabetic tissue damage during the first 6 years of NIDDM
UKPDS Group
Diabetes Care 1997;20:1435-1441. Published:Sep-1997. PMID:9283793. doi:10.2337/diacare.20.9.1435
[Abstract]

Coronary heart disease and risk factors in NIDDM - experience from the United Kingdom Prospective Diabetes Study
R. C. Turner, H. Millns, R. R. Holman
Diabetologia 1997;40 Supplement 2:S121-S122. Published:Jun-1997. PMID:9248716. doi:10.1007/s001250051424

UKPDS 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects
UKPDS Group
J Clin Endocrinol Metab 1997;82:654-657. Published:Feb-1997. PMID:9024271. doi:10.1210/jcem.82.2.3744
[Abstract]

UKPDS 21: low prevalence of the mitochondrial transfer RNA gene (tRNA(Leu(UUR))) mutation at position 3243bp in UK Caucasian type 2 diabetic patients
Saker PJ, Hattersley AT, Barrow B, Hammersley MS, Vorton H, Gillmer MD, Turner RC
Diab Med. 1997;14:42-45. Published:Jan-1997. PMID:9017352. doi:10.1002/(SICI)1096-9136(199701)14:1<42::AID-DIA295>3.0.CO;2-T
[Abstract]

Issues in Management: Diabetes
Holman RR, Neil HAW
Prevention of Cardiovascular Disease. Ed. Lawrence M 1996;OUP:0. Published:11-Sep-2006

UKPDS 19: Heterogeneity in NIDDM: separate contributions of IRS-1 and b3-adrenergic-receptor mutations to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations
Zhang Y, Wat N, Stratton IM, Warren-Perry MG, Orho M, Groop L, Turner RC
Diabetolgia 1996;39:1505-1511. Published:Dec-1996. PMID:8960833. doi:10.1007/s001250050605
[Abstract]

High prevalence of a missense mutation of the glucokinase gene in gestational diabetic patients due to a founder-effect in a local population
Saker PJ, Hattersley AT, Barrow B, Hammersley MS, McLellan JA, D Lo YM, Olds RJ, Gillmer MD, Holman RR, Turner RC
Diabetologia 1996;39:1325-1328. Published:Nov-1996. PMID:8932999. doi:10.1007/s001250050577
[Abstract]

Hypertension in Diabetes Study (HDS) IV: Therapeutic requirements to maintain tight blood pressure control
Hypertension in Diabetes Study Group
Diabetologia 1996;39:1554-1561. Published:Nov-1996. PMID:8960842. doi:10.1007/s001250050614
[Abstract]

The UK Prospective Diabetes Study
Turner RC, Holman RR
Ann Med. 1996;28:439-444. Published:Oct-1996. PMID:8949976
[Abstract]

Randomized controlled pilot trial of a hand-held, patient-oriented, insulin regimen optimizer
Holman RR, Smale AD, Pemberton E, Riefflin A, Nealon JL
Med Inform. 1996;21:317-326. Published:Oct-1996. PMID:9179835. doi:10.3109/14639239608999292
[Abstract]

UKPDS 18: estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy
UKPDS Group
Diab Med. 1996;13:656-662. Published:Jul-1996. PMID:8840101. doi:10.1002/(SICI)1096-9136(199607)13:7<656::AID-DIA131>3.0.CO;2-5
[Abstract]

Frequency of hypoglycemic episodes during intensive therapy with human insulin
Turner RC, Cull CA, Holman RR
Diabetes Care 1996;19:181-182. Published:Feb-1996. PMID:8718446. doi:10.2337/diacare.19.2.181b

U.K. Prospective Diabetes Study
Turner RC, Cull CA, Holman RR
Diabetes Care 1996;19:182-183. Published:Feb-1996. PMID:8718447. doi:10.2337/diacare.19.2.182

United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus
UKPDS Group
Annals of Internal Medicine 1996;124:136-145. Published:01-Jan-1996. PMID:8554206. doi:10.7326/0003-4819-124-1_Part_2-199601011-00011
[Abstract]

Impaired Glucose Tolerance
Holman RR
Diab Med. 1996;13:S5. Published:Jan-1996

Intensive treatment of type 2 diabetes
Turner RC, Rachman J, Holman RR
Home P, Ed. Copenhagen Symposium Diabetes - the Challenge. Copenhage: Medical Forum International 1996;13-16. Published:Jan-1996